<SEC-DOCUMENT>0001047469-20-003852.txt : 20200625
<SEC-HEADER>0001047469-20-003852.hdr.sgml : 20200625
<ACCEPTANCE-DATETIME>20200625091441
ACCESSION NUMBER:		0001047469-20-003852
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200625
DATE AS OF CHANGE:		20200625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-239389
		FILM NUMBER:		20987149

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2241966z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg70401_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-239389  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="26%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount to be<BR>
Registered<SUP>(1)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Offering Price per<BR>
Share</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price<SUP>(1)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee<SUP>(2)</SUP></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Common Stock, par value $0.0001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6,900,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$31.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$215,625,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>$27,989</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Includes
900,000 shares of Common Stock that may be purchased by the underwriter pursuant to its option to purchase additional shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Calculated
in accordance with Rule&nbsp;456(b) and 457(r) under the Securities Act of 1933, as amended. This "Calculation of Registration Fee" table shall be
deemed to update the "Calculation of Registration Fee" table in the registrant's Registration Statement on Form&nbsp;S-3ASR (File No.&nbsp;333-239389).  </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=719681,FOLIO='blank',FILE='DISK103:[20ZCV1.20ZCV70401]AA70401A.;3',USER='SCAVALI',CD='24-JUN-2020;12:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT COLOR="#F1665F" SIZE=3><I>PROSPECTUS</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>6,000,000 Shares  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>
<IMG SRC="g205044.jpg" ALT="LOGO" WIDTH="228" HEIGHT="100">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>Common Stock  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=3><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I>Editas Medicine,&nbsp;Inc. is offering 6,000,000 shares of its common stock.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I>Our common stock is listed on The Nasdaq Global Select Market under the symbol "EDIT." The last reported sale price of our common stock on The Nasdaq
Global Select Market on June&nbsp;23, 2020 was $34.34 per share.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=3><B><I>Investing in our common stock involves risks. See "Risk Factors" beginning on page&nbsp;11 of this prospectus,
as well as those contained in the documents incorporated by reference herein.</I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p><div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </I></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Price to<BR>
public

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Underwriting<BR>
Discounts and<BR>
Commissions<SUP>(1)</SUP>

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Proceeds to<BR>
Editas

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B><I> </I></B></FONT><FONT SIZE=2><I>Per Share </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$31.25</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$1.70</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$29.55</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2><I> </I></FONT><FONT SIZE=2><I>Total </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$187,500,000</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$10,200,000</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$177,300,000</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>See "Underwriter" beginning on page&nbsp;24 of this prospectus. </I></FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>We have granted the underwriter an option to purchase up to an additional 900,000 shares of our common stock at the public offering price less the underwriting discounts and
commissions. The underwriter can exercise this option at any time within 30&nbsp;days after the date of this prospectus.  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>The underwriter expects to deliver the shares of common stock to investors on or about June&nbsp;26, 2020.  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>MORGAN STANLEY  </I></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><I>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</i></font></p><p align=left style="font-family:times;"><font></FONT><FONT SIZE=2><I>The date of this prospectus is June&nbsp;23, 2020.</I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=457081,FOLIO='blank',FILE='DISK103:[20ZCV1.20ZCV70401]BC70401A.;14',USER='JLAWRENA',CD='24-JUN-2020;12:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_bg70401_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="BG70401A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg70401_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg70401_prospectus"> </A></FONT> <FONT SIZE=2><B>  PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<A NAME="BG70401_TOC2"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi70401_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi70401_forward-looking_statements"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca70401_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca70401_prospectus_summary"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da70401_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da70401_risk_factors"><FONT SIZE=2>11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da70401_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da70401_use_of_proceeds"><FONT SIZE=2>12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da70401_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da70401_dividend_policy"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da70401_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CAPITALIZATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da70401_capitalization"><FONT SIZE=2>14</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da70401_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da70401_dilution"><FONT SIZE=2>15</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#db70401_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#db70401_description_of_capital_stock"><FONT SIZE=2>16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc70401_material_u.s._tax_consideratio__mat02573"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL U.S. TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON
STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc70401_material_u.s._tax_consideratio__mat02573"><FONT SIZE=2>20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de70401_underwriter"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITER</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de70401_underwriter"><FONT SIZE=2>24</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di70401_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di70401_legal_matters"><FONT SIZE=2>35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di70401_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di70401_experts"><FONT SIZE=2>35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#h1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#h1"><FONT SIZE=2>36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#h2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#h2"><FONT SIZE=2>37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not, and the underwriter has not, authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this
prospectus or in any free writing prospectus we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is
current only as of its date. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>No action is being taken in any jurisdiction outside the United States to permit a public offering of the securities or possession or distribution of this
prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions
as to this offering and the distribution of this prospectus applicable to that jurisdiction.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=892945,FOLIO='i',FILE='DISK103:[20ZCV1.20ZCV70401]BG70401A.;10',USER='CHE107604',CD='23-JUN-2020;02:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_bi70401_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi70401_forward-looking_statements"> </A>
<A NAME="toc_bi70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus and the information incorporated by reference herein include "forward-looking statements" within the meaning of
Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts
included in this prospectus and the information incorporated herein by reference, including statements regarding our future results of operations and financial position,
business strategy, and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important
factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking
statements. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus and the information
incorporated herein by reference are only predictions. We have based these forward-looking statements largely on our expectations and projections about future events and financial trends that we
believe may affect our business, financial condition, results of operations, and prospects, in each case as of the time we made such forward-looking statement. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions. We have included important factors in the cautionary statements included in this prospectus and the information incorporated by reference
herein, particularly under the heading "Risk Factors" in this prospectus and in the documents incorporated by reference herein, that could cause actual results or events to differ materially from the
forward-looking statements that we make. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on
these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained or
incorporated by reference herein. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=121577,FOLIO='1',FILE='DISK103:[20ZCV1.20ZCV70401]BI70401A.;7',USER='MTITUSS',CD='23-JUN-2020;07:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_ca70401_1_2"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca70401_prospectus_summary"> </A>
<A NAME="toc_ca70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights selected information contained elsewhere in this prospectus and in the documents we incorporate
herein by reference. This summary does not contain all of the information that you should consider before investing in our common stock. You should read this entire prospectus carefully, especially
the risks of investing in our common stock discussed under "Risk Factors" beginning on page&nbsp;11 of this prospectus and in the "Risk Factors" section of our
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020001476/edit-20191231x10k624cb2.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020005883/edit-20200508x10q.htm">our Quarterly Report on Form&nbsp;10-Q for the quarterly period
ended March&nbsp;31, 2020,</A> along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in
this prospectus, before making an investment decision.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a leading, clinical stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad
range of serious diseases. The promise of genomic medicines is supported by the advancing knowledge of the human genome, and harnessing the progress in technologies for cell therapy, gene therapy,
and, most recently, genome editing. We believe this progress sets the stage for us to create unprecedented medicines with the potential to have a durable benefit for patients. At Editas Medicine, our
core capability in genome editing uses the technology known as CRISPR (clustered, regularly interspaced, short palindromic repeats) with which we can create molecules that efficiently and specifically
edit DNA. Our mission is to translate the promise of genome editing into a broad class of differentiated, transformational medicines for diseases of high unmet need. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are advancing both </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside
their body, and engineered cell medicines, in which cells are edited with our technology and then administered to the patient. For our </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> CRISPR
medicines, we are leveraging an adeno-associated virus ("AAV")-mediated editing platform with our proprietary </FONT><FONT SIZE=2><I>Staphylococcus aureus</I></FONT><FONT SIZE=2> Cas9 ("SaCas9") to
develop these medicines. In ocular diseases, our most advanced program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10 ("LCA10"), a disease
for which we are not aware of any available therapies and only one other potential treatment in clinical trials in the United States and Europe. In mid-2019, we initiated a Phase 1/2 clinical trial
for EDIT-101 (also known as AGN-151587), an experimental medicine to treat LCA10, pursuant to an investigational new drug application ("IND") that we filed in
October 2018 and which was accepted by the United States Food and Drug Administration ("FDA") in November 2018. In March 2020, we and our partner Allergan Pharmaceuticals International Limited
(together with its affiliates, "Allergan"; in May 2020, Allergan was acquired by AbbVie Inc.) announced the first patient dosing in this clinical trial. We expect to enroll approximately 18 patients
in the United States and Europe in up to five cohorts. We aim to complete dosing of the adult low-dose cohort and to dose at least one patient in the adult mid-dose cohort by the end of 2020 with the
potential for data also by the end of 2020. In addition, we initiated a clinical natural history study in 2017 to evaluate the clinical course and characteristics of LCA10 more extensively. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe preclinical results to date with EDIT-101 validate our platform technology, including its potential application to other ocular diseases, such as Usher syndrome 2A ("USH2A")
and autosomal dominant retinitis pigmentosa 4 ("adRP4"), as well as diseases of other organs and tissues. In 2019, we achieved </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> preclinical proof
of concept and declared a development candidate, referred to as EDIT-102, for USH2A. In 2019, we also advanced preclinical studies for our adRP4 program. We are leveraging our AAV-mediated editing
platform and expertise in ocular therapies to pursue additional therapeutic areas to treat other organ and tissues that are accessible by AAV. For example, in 2019, we entered into a strategic
research collaboration with Asklepios BioPharmaceutical,&nbsp;Inc., a fully integrated AAV gene therapy company ("AskBio"), to explore the use of our AAV-mediated editing platform to treat
neurological diseases. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=303366,FOLIO='2',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to developing </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> CRISPR medicines, the development of engineered cell medicines is a core part of our research effort and
product pipeline. We believe that advances in genome editing will both improve the characteristics of current cellular medicines and also expand the universe of cellular medicines that can be
developed. To this end, we have established capabilities to efficiently and specifically edit hematopoietic stem cells ("HSCs"), natural killer ("NK") cells and T cells, which we believe can lead to
best-in-class medicines for hemoglobinopathies and cancer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
our engineered cell medicines, our lead program is EDIT-301, an experimental medicine to treat sickle cell disease and beta-thalassemia. We have initiated IND-enabling studies for
EDIT-301 and aim to file an IND for EDIT-301 for sickle cell disease by the end of 2020. The CRISPR nuclease used in our EDIT-301 program is a proprietary engineered form of Cas12a for which we have
exclusively licensed the foundational intellectual property to develop and commercialize human therapeutics. We
believe our editing approach, including targeting the </FONT><FONT SIZE=2><I>HBG1/2</I></FONT><FONT SIZE=2> gene and the use of Cas12a, differentiates us from other genome editing companies working
on sickle cell disease and positions us to develop a potentially best-in-class medicine to treat sickle cell disease and beta-thalassemia. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also continued to develop our capabilities to generate cells from induced pluripotent stem cells ("iPSCs") and to edit cells obtained from healthy donors to develop engineered
cell medicines to treat cancer. For example, in 2019, we advanced engineered iPSC-derived NK ("iNK") cell medicines for solid tumors using technology from BlueRock Therapeutics&nbsp;LP ("BlueRock")
and generated edited NK cells from both healthy donors and iPSCs with significantly increased anti-cancer activity. In 2020, we initiated IND-enabling studies for EDIT-201, an engineered healthy donor
NK (HDNK) cell medicine to treat solid tumors. We are also advancing alpha-beta T cell medicines in collaboration with Juno Therapeutics,&nbsp;Inc., a wholly owned subsidiary of Bristol-Myers Squibb
Company ("Juno Therapeutics"). We believe these approaches and expertise will allow us to develop allogeneic, off-the-shelf engineered cell medicines, as opposed to relying on the need to obtain cells
directly from a patient. For our allogeneic, off the shelf medicines, we edit cells from a pool of healthy donors or from iPSCs which are subsequently differentiated into effector cells, such as NK
cells or T cells. The engineered cells are then administered to the patient. These allogeneic cell medicines have the potential to greatly reduce the costs and complexity of engineered cells and
increase the number and type of cancers that we can potentially address. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Genomic Medicine Programs  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have initiated a diversified range of research programs across multiple therapeutic and disease areas. Our product development strategy is to
target diseases where gene editing can be used to enable or enhance therapeutic outcomes for patients. We believe the therapeutic programs and delivery technologies we have chosen to date will
demonstrate the depth and breadth of our ability to deploy our genome editing </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=870968,FOLIO='3',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;text-align:justify"><FONT SIZE=2>platform
to develop differentiated, transformational medicines for patients with high unmet need. The following summarizes our research programs, product candidates and disease areas: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g427184.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="333">
  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2>In Vivo </FONT><FONT SIZE=2><I>CRISPR
Medicines&#151;Ocular</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted Allergan an exclusive option to exclusively license from us up to five collaboration development programs for the treatment of ocular disorders,
including EDIT-101. In 2018, Allergan exercised its option with respect to EDIT-101. In 2019, Allergan entered into a profit-sharing arrangement with us in the United States for such program. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Leber Congenital Amaurosis 10</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leber
congenital amaurosis ("LCA") is a heterogeneous group of inherited retinal dystrophies caused by mutations in at least 18 different genes and is the most common
cause of inherited childhood blindness, with an incidence of two to three per 100,000 live births worldwide. Symptoms of LCA appear within the first year of life with significant vision loss, rapid
involuntary movements of the eyes, painful eye response to bright light, and absence of measurable electroretinogram recordings due to a lack of functional photoreceptor cells. The most common form of
the disease is LCA10, a monogenic disorder that represents approximately 20-30% of all LCA subtypes. LCA10 is caused by autosomal recessive mutations in the CEP290 gene, which encodes a protein
required for the survival and proper function of photoreceptor cells. The most frequently found mutation within the CEP290 gene, occurring in approximately 85% of north and west European patients with
LCA10, is an A to G nucleotide change that disrupts normal splicing, or processing, of the gene message, ultimately resulting in a deficiency of functional CEP290 protein. Decreased CEP290 protein
leads to loss of the outer segments of photoreceptor cells and function over time, which leads to blindness. We believe there are between 2,000 and 5,000 LCA10 patients in the United States and
Europe. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EDIT-101
uses an AAV5 vector to deliver the DNA encoding SaCas9 and two guide RNAs to photoreceptor cells in the eye. This experimental CRISPR medicine is designed to eliminate a
disease-causing A to G nucleotide change in a non-coding region, or intron, of the CEP290 gene by cutting out that nucleotide and surrounding DNA. We believe this genome editing approach has the
potential to restore normal protein expression and function of the remaining photoreceptor cells, which could improve vision or arrest the further loss of vision in LCA patients. Certain clinical
research studies estimated that </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=818686,FOLIO='4',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>retention
of 10% of photoreceptors can impart meaningful vision in humans. Based on these studies, we have prespecified a therapeutic target of 10% productive editing of photoreceptors with the
assumption that each productively edited photoreceptor will be fully functional. We have tested EDIT-101 in preclinical studies by delivering several dose quantities of EDIT-101 subretinally in mice
that had a humanized CEP290 gene. Subretinal delivery of EDIT-101 in humanized CEP290 mice showed rapid and sustained CEP290 gene editing. These studies demonstrated that EDIT-101 edited the relevant
cells at therapeutically relevant levels as early as a week following dosing and greater than 10% editing at AAV dose levels that have been safely administered to humans based on prior clinical
studies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
investigate genome editing </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>, we conducted studies in non-human primates using subretinal injection of an AAV5 expressing SaCas9
and nonhuman primate specific guide RNAs. After either six or 13&nbsp;weeks, animals were euthanized and retinal tissue from the injected region was removed for analysis. These studies showed that
AAV genomes and Cas9 expression were limited to photoreceptors. In addition, we estimate that 12-22% and 50% of CEP-290 alleles were productively edited at six weeks and at 13&nbsp;weeks,
respectively. In these studies, productive editing is defined as the proportion of photoreceptor cells edited in a manner that we believe will restore CEP290 protein function. All of these values
exceed our prespecified therapeutic target of 10% productive editing. Furthermore, these doses were shown in subsequent studies to be well tolerated in non-human primates based on visual and
immunohistochemical analysis. Similar studies in mice showed that editing was rapid, achieving maximum levels by six weeks, and stable with changes maintained for the 26&nbsp;weeks of the study at
an AAV dose that has been safely administered to humans. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, we initiated a natural history study of LCA10 patients. In this study, we are assessing the manifestations and course of the LCA10 disease in approximately 40 patients across a
range of ages
and disease severity at seven sites in the United States and Europe. Patients are evaluated six times over the course of a year. The purpose of the study was to inform the clinical trial design and
enrollment for our Phase 1/2 clinical trial of EDIT-101 through the characterization of patients' baseline status and the rate of change of the disease, as well as to validate endpoints of the Phase
1/2 clinical trial for EDIT-101. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
mid-2019, we and Allergan initiated an initial Phase 1/2 clinical trial which is an open-label, single ascending dose trial of EDIT-101 in adult and pediatric (i.e.,&nbsp;ages 3 to
17&nbsp;years) patients with retinal degeneration caused by a homozygous or compound heterozygous mutation of the CEP290 gene, which is referred to as an IVS26 mutation. Patients will receive a
single dose of EDIT-101 administered via subretinal injection in one eye. Approximately 18 patients will be enrolled at approximately eight trial centers in the United States and Europe. Up to five
cohorts across three doses will be enrolled in this clinical trial. The primary endpoint of the trial is an assessment of safety and tolerability, and the secondary endpoint is to evaluate the
efficacy of a single dose of EDIT-101 on change from baseline in various parameters. Efficacy will be evaluated at multiple timepoints, including core measures every three months for the first year
and then less frequently thereafter. In March 2020, we and Allergan announced the first patient dosing in this clinical trial. We aim to complete dosing of the adult low-dose cohort and to dose at
least one patient in the adult mid-dose cohort by the end of 2020 with the potential for data also by the end of 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2020, AbbVie&nbsp;Inc. acquired Allergan. AbbVie has already announced certain changes and may announce additional changes in Allergan's business priorities as AbbVie integrates
Allergan into its ongoing operations. AbbVie's acquisition of Allergan could affect Allergan's willingness to perform its obligations or exercise its options under our collaboration agreement with
Allergan, have an impact on Allergan's ability to retain and motivate key personnel who are important to our collaboration, and reduce or terminate its efforts on the development of our product
candidates. In addition, AbbVie could sell or otherwise dispose of our collaboration agreement and the programs under it, including the LCA10 program, or our profit-sharing agreement, or cause the
Allergan collaboration and/or the profit-sharing agreement to terminate. At this time, we are not aware of any decisions that have been made regarding our ongoing collaboration for EDIT-101 or other
option programs. Any of the foregoing that involve </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=609529,FOLIO='5',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Allergan's
collaboration with us or the LCA10 program could have an adverse effect on our collaboration with Allergan, on the LCA10 program and on the ongoing Phase&nbsp;1/2 clinical trial of
EDIT-101. In the event that Allergan terminates the collaboration agreement or the profit-sharing agreement or we otherwise reacquire the rights we have licensed to AbbVie, we would take
responsibility for the LCA10 program and the Phase&nbsp;1/2 clinical trial, which could increase our expenses or result in delays in our product timelines. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Other Eye Diseases</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also pursuing the development of therapies for eye diseases other than LCA10, including USH2A and adRP4. We believe that our experience with the LCA10 program
will support the development of therapies for these other eye diseases. For example, the successful construction and testing of the components of the AAV vector we are pursuing for EDIT-101 will
continue to inform our approach to treating the most common cause of USH2A. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Usher Syndrome 2A</U>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;USH2A gene mutations are the most common cause of Usher syndrome, a form of retinitis pigmentosa that also includes hearing loss. Loss of the
usherin protein encoded by the USH2A gene leads to a degeneration of the retina and progressive vision loss. More than 200 mutations have been identified for this gene. Our initial goal in this
research program is to address mutations within exon 13, which contains the highest percentage of USH2A gene mutations. We believe there are approximately 14,000 USH2A patients including up to
approximately 4,000 Usher syndrome patients with the mutation we aim to correct. We have declared a development candidate, EDIT-102, to treat USH2A patients. EDIT-102 is comprised of the same
proprietary enzyme, vector and promoter as EDIT-101. Under the terms of our collaboration agreement with Allergan, we have delivered a preclinical data package relating to EDIT-102 to Allergan for
potential licensing. EDIT-102 is ready for IND-enabling studies pending Allergan's option exercise. Allergan's decision is expected in the third quarter of 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
tested EDIT-102 in preclinical studies of human cell lines and demonstrated approximately 47% productive editing in the cells that resulted in such cells expressing 60% more USH2A
messenger RNA as compared to the unedited cells. In other preclinical studies, we tested EDIT-102 in humanized retinal organoids, which are three-dimensional structures derived from human pluripotent
stem cells and can serve as an in vitro model of retinas, and demonstrated noticeable increases in the proper localization of the usherin complex in the photoreceptor cells at 120-140&nbsp;days, as
compared to retinal organoids formed from cells that contained a patient-derived mutation in exon 13. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Retinitis Pigmentosa</U>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutations in the human rhodopsin ("RHO") gene accounts for 25% of all forms of adRP4, a progressive form of retinal degeneration characterized
by initial night blindness early in life followed by loss of peripheral vision and eventual complete blindness. More than 150 mutations in the RHO gene have been identified, with the most prevalent
allele in the United States representing approximately 10% of all patients with adRP4. We believe there are approximately 26,000 adRP4 patients with mutations in the RHO gene. Leveraging our EDIT-101
and EDIT-102 learnings, we are developing a novel approach to treat all forms of adRP4 resulting from mutations in the RHO gene and aim to declare a development candidate, potentially using the same
enzyme and vector as EDIT-101, by the end of 2021. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2>In Vivo </FONT><FONT SIZE=2><I>CRISPR Medicines&#151;Early Discovery
Programs</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our ocular programs, we hope to leverage our expertise in developing genomic medicines utilizing AAV delivery to expand our </FONT><FONT SIZE=2><I>in
vivo</I></FONT><FONT SIZE=2> programs to treat additional diseases and therapeutic areas, including Duchenne Muscular Dystrophy, peripheral nervous system, neuromuscular, </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=452946,FOLIO='6',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_7"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>liver,
the central nervous system and cardiology. Under our strategic research collaboration with AskBio, we are aiming to develop a therapy to treat a neurological disease and achieve an </FONT> <FONT SIZE=2><I>in-vivo</I></FONT><FONT SIZE=2> preclinical
proof-of-concept for a neurological indication in 2020. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Engineered Cell Medicines  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our most advanced engineered cell medicine, EDIT-301, is designed to treat sickle cell disease and beta-thalassemia. We are also developing
multiple engineered cell medicines for the potential treatment of different cancers, including solid tumors. In our collaboration with Juno Therapeutics, we are researching and developing engineered
alpha-beta ("<FONT FACE="SYMBOL">a</FONT><FONT FACE="SYMBOL">b</FONT>") T cell therapies to treat cancer and autoimmune diseases. In our wholly-owned oncology programs, we are
further developing our capabilities to generate certain engineered NK cells from iPSCs and healthy donor derived NK cells that we edit to treat solid tumors. We are also collaborating with Bluerock
and Sandhill Therapeutics,&nbsp;Inc. to increase our technical capabilities in such programs. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Engineered Cell Medicines&#151;Hemoglobinopathies</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are developing an approach for genome editing in HSCs to support the advancement of research programs to treat non-malignant hematological diseases, including sickle
cell disease and beta thalassemia. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients
suffering from sickle cell disease have a median life expectancy of 42-47&nbsp;years and there are over 100,000 sickle cell disease hospitalizations in the United States
annually. We are actively pursuing a distinct gene editing approach to treating these hemoglobinopathies. Our primary criteria for a successful product candidate include high and pancellular fetal
hemoglobin ("HbF") with a best-in-class safety profile. To this end, we have developed EDIT-301, an experimental, autologous cell therapy that targets the </FONT> <FONT SIZE=2><I>HBG1/2</I></FONT><FONT SIZE=2> promoter in the beta-globin gene to
stimulate HbF production, to treat sickle cell disease and plan to file an IND with the FDA by the end of
2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have focused our efforts on editing a site within the beta-globin locus that we believe has the potential to create superior expression of fetal hemoglobin since patients with
elevated fetal hemoglobin levels have better clinical outcomes. We believe that EDIT-301 has the potential to impact beta-globin expression by increasing HbF and decreasing sickle globin. In
particular, preclinical data shows that EDIT-301 induces more HbF than the approach of targeting the </FONT><FONT SIZE=2><I>BCL11A</I></FONT><FONT SIZE=2> erythroid enhancer ("BC11Ae"). Likewise, we
believe our approach will reduce the sickle globin and, therefore, not have to compete for alpha globin in the same cell unlike lentiviral gene therapy approaches. Further, human genetic studies
support editing at the beta-globin locus, but not at the </FONT><FONT SIZE=2><I>BC11Ae</I></FONT><FONT SIZE=2> locus. Our preclinical studies also identified one potential concern for </FONT> <FONT SIZE=2><I>BC11Ae</I></FONT><FONT SIZE=2> editing as
we found deleterious lineage skewing when editing the </FONT><FONT SIZE=2><I>BCL11Ae</I></FONT><FONT SIZE=2> locus. Finally, gene
editing is more specific than lentiviral expression. To get the high levels of beta-globin required for an efficacious therapy, there will be cells in the CD34+ population, which are cells that
contain the long-term stem cells that repopulate
the hematopoietic lineages, that carry more than twenty copies of the viral genome. These random integration events have the potential to inadvertently activate or inactivate genes involved in cell
function and tumorigenesis. As such, we believe our approach to editing the beta-globin locus provides the highest likelihood of providing clinical benefit in patients while working to minimize
potential safety risks. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our belief that editing the beta-globin locus is the preferred therapeutic approach, we conducted a comprehensive screen of the beta-globin locus for sites that would elevate
fetal hemoglobin. In particular, we screened over 26,000 guide RNAs spanning a 300 kb region of the beta-globin locus. This screen was successful in identifying several sites, including those
predicted by human genetics, that elevate HbF. We then examined whether Cas9 or Cas12a was the preferred editing enzyme. We found that indels, which are small insertions and deletions at the cut site,
larger than three nucleotide deletions induced more HbF than smaller deletions and that indels created by non-homologous end joining ("NHEJ") repair </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=147539,FOLIO='7',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_8"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>process
are preferentially retained </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> compared to indels created by microhomology-mediated end joining repair process. Finally, we found that
Cas12a makes more larger deletions by NHEJ than Cas9. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
our approach in preclinical studies, we edited human CD34+ cells at the </FONT><FONT SIZE=2><I>HBG1/2</I></FONT><FONT SIZE=2> promoter site and then infused these edited cells
into immuno-compromised mice. Following such infusion, we collected bone marrow from the mice at eight- and 16-weeks post-infusion. Such studies demonstrated that the edited cells were able to
repopulate all hematopoietic lineages, including red blood cell precursors, in the mice, resulting in increased production of fetal hemoglobin, with similar levels of cell death as compared to
unedited cells. In contrast, we found that cells edited at the </FONT><FONT SIZE=2><I>BCL11A</I></FONT><FONT SIZE=2> erythroid enhancer site were not able to fully repopulate the erythroid lineage in
mice and experienced increased levels of cell death as compared to unedited cells. If these results are seen in humans, then editing at the </FONT><FONT SIZE=2><I>BCL11A</I></FONT><FONT SIZE=2>
erythroid enhancer site may not be an effective approach to treat sickle cell disease or beta-thalassemia. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also tested the ability of CD34+ cells obtained from healthy donors and edited at the beta-globin locus to induce fetal hemoglobin. As predicted from our </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> studies, editing at the beta-globin site
with Cas12a caused a robust induction of HbF with approximately 45% above the background levels and HbF induction was pancellular. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also tested CD34+ cells obtained from sickle cell patients and edited at the beta-globin locus. These studies showed that editing was highly efficient and reproducible, with
approximately 90&nbsp;percent editing in multiple sickle patient donors. We found EDIT-301 derived red blood cells had more than 50&nbsp;percent HbF expression. Further, EDIT-301 derived red blood
cells had a significant improvement in deformability, which could aid red blood cell transit without sickling, and a four-fold decrease in sickling, when subjected to reduced oxygen levels compared to
unedited control cells. These data suggest EDIT-301 can provide potential clinical benefit for sickle patients. In vivo studies revealed editing was highly efficient with greater than
90&nbsp;percent editing in bone marrow cells from mice infused with edited CD34+ cells 16&nbsp;weeks post infusion. In these mice, HbF expression was increased by approximately 50&nbsp;percent
in the red blood cells derived from these edited cells. We also observed that approximately 90&nbsp;percent of these cells were HbF positive, demonstrating that HbF expression was pan-cellular, a
likely critical property for potential clinical benefit. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
data demonstrate that editing at the beta-globin locus induces robust levels of HbF that are pancellular and does not cause lineage skewing. For these reasons, we believe our
approach of editing the hemoglobin locus to increase fetal hemoglobin has the potential to generate differentiated medicines to benefit patients with sickle cell disease and beta thalassemia. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Engineered Cell Medicines&#151;Alpha-Beta T Cells</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Engineered
T cells, including alpha-beta T cells, have shown encouraging clinical activity against multiple cancers, culminating in the recent approval of two such
therapies in the United States. Because of these promising results, there is significant interest in the medical community in expanding the application of this technology across a broader range of
cancers and patients. We believe that our genome editing technology has the potential to improve multiple properties of these alpha-beta T cell therapies. Alpha-beta cells are part of the adaptive
immune system and recognize tumors with endogenous alpha-beta T cell receptors or chimeric antigen receptors ("CARs") or engineered T cell receptors ("Engineered TCRs"). If we are successful,
genome-edited engineered alpha-beta T cells have the potential to significantly expand the types of cancers treatable by CAR/ Engineered TCR alpha-beta T cells and to improve the outcomes of these
therapies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
our collaboration with Juno Therapeutics, we have applied our genome editing technology to multiple gene targets in order to improve the efficacy and safety of CAR/ Engineered
TCR alpha-beta T cells directed against a range of tumor types. In addition, we have optimized genome editing components and delivery methods compatible with engineered alpha-beta T cell manufacturing
methods developed by Juno Therapeutics. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=701821,FOLIO='8',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<A NAME="page_ca70401_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Engineered Cell Medicines&#151;Natural Killer Cells and Gamma Delta T
Cells</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are developing engineered NK cell medicines to treat solid tumors. NK cells are innate immune cells that can recognize tumor cells by a variety of mechanisms,
including multiple innate receptors that recognize cells that do not express T cell antigens and cells that express stress ligands. NK cells are also part of a process known as antibody-directed
cellular cytotoxicity ("ADCC") by which therapeutic antibodies are directed to and kill tumor cells. Further, NK cells have a lower risk of causing graft versus host disease. If we are successful,
genome-edited NK cells have the potential to increase the signaling power of ADCC pathways, improve the persistence of NK cells and/or increase tumor microenvironment resistance. Genome-edited NK
cells may be further engineered with one or more CARs or innate receptors to further improve one or more of these properties. For example, genome-edited engineered NK cells could be used to improve
recognition of tumor cells lacking T cell antigens, including PD-1 non-responding tumors. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
two primary approaches to obtaining NK cells are obtaining such cells from healthy donors or differentiating iPSCs into such cells. Once we have obtained the cells, we then edit them
to increase certain of the natural properties of the cell to better enable them to treat solid tumors, such as the cells persistence </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2>, its
ability to withstand the tumor micro-environment, improved ability to cause ADCC and improved recognition of tumor cells. In preclinical studies, we have demonstrated our ability to efficiently edit
healthy donor derived NK cells which resulted in a 54% increase in the amount of cytolysis in cultured cells, as compared to unedited NK cells. Further, we efficiently edited five genes in iPSCs at
70-100% levels. For one such edited iPSC, the resulting edited iNKs killed 74% of cultured cells while unedited cells only killed 2% of cultured cells. In 2020, we initiated IND-enabling studies for
EDIT-201, an engineered healthy donor NK (HDNK) cell medicine to treat solid tumors. By the end of 2020, we aim to achieve </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> preclinical
proof-of-concept for our iPSC-derived NK cell program, in each case, to treat solid tumors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also begun researching and developing gamma delta T cell therapies to treat cancer. Like NK cells, gamma delta T cells are part of the innate immune system. We hope to leverage
our capabilities and expertise in alpha-beta T cells and our NK cell programs to develop such therapies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Corporate Information  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive offices are located at 11 Hurley Street, Cambridge, Massachusetts, 02141, and our telephone number is (617)&nbsp;401-9000. Our
website address is www.editasmedicine.com. We have included our website address in this prospectus as an inactive textual reference only. Information contained on, or that can be accessed through, our
website is not part of this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this prospectus, unless otherwise stated or the context otherwise requires, references to "Editas," "we," "us," "our," and similar references refer to Editas Medicine,&nbsp;Inc. and
its consolidated subsidiary. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Editas logo is our trademark. The other trademarks, trade names, and service marks appearing in this prospectus belong to their respective holders. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=202764,FOLIO='9',FILE='DISK103:[20ZCV1.20ZCV70401]CA70401A.;28',USER='JFUSS',CD='23-JUN-2020;12:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_cc70401_1_10"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc70401_the_offering"> </A>
<A NAME="toc_cc70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>6,000,000 shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Common stock to be outstanding after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>61,230,261 shares (or 62,130,261 shares if the underwriter exercises its option to purchase additional shares in full).</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We have granted the underwriter an option for a period of 30&nbsp;days to purchase up to 900,000 additional shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>We estimate that the net proceeds to us from this offering will be approximately $177.0&nbsp;million (or $203.6&nbsp;million if the underwriter exercises its option to purchase additional shares in full), after
deducting underwriting discounts and commissions and estimated offering expenses payable by us. We currently intend to use the net proceeds to us from this offering to fund the Phase&nbsp;1/2 clinical trial for EDIT-101, the research, development and
preclinical studies for our other </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> CRISPR medicine research programs, including EDIT-102, our engineered cell medicines research programs, including EDIT-301, and for working capital and other
general corporate purposes. See "Use of Proceeds" for more information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>See "Risk Factors" beginning on page&nbsp;11 and the other information included in, or incorporated by reference into, this prospectus for a discussion of certain factors you should carefully consider before deciding
to invest in shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2>Nasdaq Global Select Market symbol</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>"EDIT"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering is based on the 55,230,261 shares of our common stock outstanding as of May&nbsp;31, 2020, which includes
180,000 shares of unvested restricted stock subject to repurchase by us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 4,133,917 shares of common stock issuable upon exercise of stock options outstanding as May&nbsp;31, 2020, at a weighted-average exercise
price of $26.41 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 346,912 shares of common stock issuable upon vesting of restricted stock unit awards outstanding as May&nbsp;31, 2020; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 5,792,915 additional shares of common stock reserved as of May&nbsp;31, 2020 for future issuance under our 2015 Stock Incentive Plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,160,492 additional shares of common stock reserved as of May&nbsp;31, 2020 for future issuance under our 2015 Employee Stock Purchase Plan;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any shares of common stock that we may issue in satisfaction of certain payment obligations of ours under certain license agreements to which
we are a party and certain promissory notes that we expect we may issue in the future in connection with these license agreements. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated, this prospectus reflects and assumes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> no exercise of the outstanding options described above; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> no exercise by the underwriter of its option to purchase additional shares of our common stock. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=698673,FOLIO='10',FILE='DISK103:[20ZCV1.20ZCV70401]CC70401A.;14',USER='MTITUSS',CD='24-JUN-2020;12:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_da70401_1_11"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da70401_risk_factors"> </A>
<A NAME="toc_da70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock,
you should consider carefully the risks and uncertainties described below and under the section captioned "Risk Factors" contained in our most recent Annual Report on Form&nbsp;10-K and Quarterly
Reports on Form&nbsp;10-Q and other filings we make with the Securities and Exchange Commission from time to time, which are incorporated by reference herein in their entirety, together with the
other information in this prospectus, or incorporated by reference herein, and in any free writing prospectus that we authorize for use in connection with this offering. If any of these risks actually
occurs, our business, financial condition, results of operations or cash flow could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part
of your investment.</I></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to This Offering  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase shares of common stock in this offering, you will suffer immediate dilution of your
investment.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you purchase common stock in this offering, you will incur immediate and substantial dilution of $24.50 per share, representing the
difference between the public offering price of $31.25 per share and our as adjusted net tangible book value per share after giving effect to this offering at the public offering price. Moreover, as
of May&nbsp;31, 2020, there were 4,133,917 shares subject to outstanding options at a weighted-average exercise price of $26.41 per share and 346,912 shares subject to outstanding restricted stock
unit awards. To the extent that these outstanding options are ultimately exercised or the underwriter exercises its option to purchase additional shares, you may incur further dilution. For a further
description of the dilution you may experience immediately after this offering, see "Dilution." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience future dilution as a result of future equity offerings.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or
exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is
less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per
share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid
by investors in this offering. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may also in certain circumstances issue shares of our common stock in satisfaction of certain payment obligations of ours under certain license agreements to which we are a party and
promissory
notes that we expect we may issue in the future in connection with these license agreements. To the extent that we issue these shares for consideration per share that is less than the price per share
paid by investors in this offering, you will incur further dilution. For more information, see "Business&#151;Our Collaborations and Licensing Strategy" in our
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020001476/edit-20191231x10k624cb2.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, as
filed with the Securities and Exchange Commission on February&nbsp;26, 2020</A> and incorporated by reference herein. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion over the use of our cash, cash equivalents and marketable securities, including the
net proceeds we receive in this offering, and may not use them effectively.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management has broad discretion to use our cash, cash equivalents and marketable securities, including the net proceeds we receive in this
offering, to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply
these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our
product candidates. Pending their use to fund operations, we may invest our cash, cash equivalents and marketable securities in a manner that does not produce income or that loses value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=14,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=206764,FOLIO='11',FILE='DISK103:[20ZCV1.20ZCV70401]DA70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:22' -->
<A NAME="page_da70401_1_12"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da70401_use_of_proceeds"> </A>
<A NAME="toc_da70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds to us from this offering will be approximately $177.0&nbsp;million, or approximately $203.6&nbsp;million
if the underwriter exercises in full its option to purchase additional shares of our common stock, in each case after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently intend to use the net proceeds to us from this offering to fund the Phase 1/2 clinical trial for EDIT-101, the research, development and preclinical studies for our other </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> CRISPR
medicine research programs, including EDIT-102, our engineered cell medicines research programs, including EDIT-301, and for working
capital and other general corporate purposes. We believe opportunities may
exist from time to time to expand our current business through acquisitions of or license or collaboration agreements with complementary companies, products, or technologies. While we have no current
agreements, commitments or understandings for any specific acquisitions or license or collaboration agreements at this time, we may use a portion of the net proceeds for these purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
expected use of the net proceeds to us from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of our actual
expenditures may vary significantly depending on numerous factors, including the progress of our research and development efforts, the status of and results from clinical trials, any collaborations
that we may enter into with third parties for our programs, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this
offering. As of March&nbsp;31, 2020, we had cash, cash equivalents and marketable securities of $415.0&nbsp;million. We estimate that the net proceeds from this offering, together with our
existing cash, cash equivalents and marketable securities, and anticipated interest income, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at
least the next 24&nbsp;months. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not
expect that the net proceeds from this offering and our existing cash, cash equivalents and marketable securities will be sufficient to enable us to fund the completion of development of any product
candidates we may develop. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
our use of the proceeds as described above, we intend to invest the proceeds in short-term, interest-bearing, investment-grade securities and U.S. government securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=15,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=739551,FOLIO='12',FILE='DISK103:[20ZCV1.20ZCV70401]DA70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:22' -->
<A NAME="page_da70401_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da70401_dividend_policy"> </A>
<A NAME="toc_da70401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and
expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=16,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=51852,FOLIO='13',FILE='DISK103:[20ZCV1.20ZCV70401]DA70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:22' -->
<A NAME="page_da70401_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da70401_capitalization"> </A>
<A NAME="toc_da70401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our cash, cash equivalents, marketable securities and capitalization as of March&nbsp;31, 2020, as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on an actual basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on an as adjusted basis to give effect to our issuance and sale of 6,000,000 shares of common stock in this offering at the public offering
price of $31.25 per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read the following table together with our consolidated financial statements and the related notes to those statements and the "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in our <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020001476/edit-20191231x10k624cb2.htm">Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2019</A> and our
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020005883/edit-20200508x10q.htm">Quarterly Report on Form&nbsp;10-Q for the quarterly period ended March&nbsp;31,
2020</A>, which are incorporated by reference into this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of March&nbsp;31, 2020<BR>
(unaudited) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As Adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>414,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>592,040 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease liabilities, net of current portion</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,530</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,530</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock, par value $0.0001 per share; 5,000,000 shares authorized no shares issued or outstanding</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, par value $0.0001 per share, 195,000,000 shares authorized; 54,982,399 and 60,982,399&nbsp;shares issued, actual and as adjusted; and
54,802,399 and 60,802,399&nbsp;shares outstanding, actual and as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>820,813</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>997,859</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>694</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>694</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(586,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(586,945</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>234,567</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411,614 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>256,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>433,144 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table above does not include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 4,547,827 shares of common stock issuable upon exercise of stock options outstanding as of March&nbsp;31, 2020, at a weighted-average
exercise price of $26.00 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 385,828 shares of common stock issuable upon vesting of restricted stock unit awards outstanding as of March&nbsp;31, 2020; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 5,762,951 shares of common stock reserved as of March&nbsp;31, 2020 for future issuance under our 2015 Stock Incentive Plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,175,736 additional shares of our common stock available for future issuance as of March&nbsp;31, 2020 under our 2015 Employee Stock
Purchase Plan. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=17,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=320210,FOLIO='14',FILE='DISK103:[20ZCV1.20ZCV70401]DA70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:22' -->
<A NAME="page_da70401_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da70401_dilution"> </A>
<A NAME="toc_da70401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the price per share you pay
in this offering and the as adjusted net tangible book value per share of our common stock after this offering. Our net tangible book value as of March&nbsp;31, 2020 was $234.6&nbsp;million, or
$4.27 per share of common stock based upon 54,982,399 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total
number of shares outstanding as of March&nbsp;31, 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to our issuance and sale of 6,000,000 shares of our common stock in this offering at the public offering price of $31.25 per share, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March&nbsp;31, 2020 would have been $411.6&nbsp;million, or $6.75 per share
of common stock. This represents an immediate increase in net tangible book value of $2.48 per share to our existing stockholders and an immediate dilution of $24.50 per share to new investors in this
offering. The following table illustrates this calculation on a per share basis. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net tangible book value per share as of March&nbsp;31, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to sale of shares of common stock in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As adjusted net tangible book value per share after giving effect to this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.75 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24.50 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the underwriter exercises its option to purchase additional shares in this offering in full, the as adjusted net tangible book value after the offering would be $7.08 per share, the
increase in as adjusted net tangible book value per share to existing stockholders would be $2.81 and the dilution per share to new investors would be $24.17 per share, in each case after deducting
underwriting discounts and commissions and estimated offering expenses payable by us. If any shares are issued upon exercise of outstanding options or vesting of restricted stock unit awards at
exercise prices below the public offering price in this offering, you will experience further dilution. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing table and calculations are based on the 54,982,399 shares of our common stock outstanding as of March&nbsp;31, 2020 which includes 180,000 shares of unvested restricted
stock subject to repurchase by us and excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 4,547,827 shares of common stock issuable upon exercise of stock options outstanding as of March&nbsp;31, 2020, at a weighted-average
exercise price of $26.00 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 385,828 shares of common stock issuable upon vesting of restricted stock unit awards outstanding as of March&nbsp;31, 2020; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 5,762,951 shares of common stock reserved as of March&nbsp;31, 2020 for future issuance under our 2015 Stock Incentive Plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,175,736 additional shares of our common stock available for future issuance as of March&nbsp;31, 2020 under our 2015 Employee Stock
Purchase Plan. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=18,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=179665,FOLIO='15',FILE='DISK103:[20ZCV1.20ZCV70401]DA70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:22' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_db70401_1_16"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="db70401_description_of_capital_stock"> </A>
<A NAME="toc_db70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock.
This description is based upon, and is qualified by reference to, our restated certificate of incorporation, our amended and restated by-laws and applicable provisions of Delaware corporate law. You
should read our restated certificate of
incorporation and amended and restated by-laws, which are filed as exhibits to the registration statement of which this prospectus forms&nbsp;a part, for the provisions that are important to you. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
authorized capital stock consists of 195,000,000 shares of common stock, par value $0.0001 per share, and 5,000,000 shares of preferred stock, par value $0.0001 per share. As of May
31, 2020, 55,230,261 shares of common stock were outstanding, which were held of record by 14&nbsp;stockholders (not including beneficial owners whose shares are held in street name), and no shares
of preferred stock were outstanding. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Annual meetings of our stockholders are held on the date designated in accordance with our amended and restated by-laws.
Written
notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60&nbsp;days before the date of the meeting. The presence in person or by proxy of the holders of record of
a majority of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the
stockholders may be called for any purpose, and may be called only by the board of directors, the chairman of the board, or the chief executive officer, and business to be transacted at any special
meeting is limited to matters related to the purpose or purposes stated in the notice of the meeting. Except as may be otherwise provided by applicable law, our restated certificate of incorporation,
or our amended and restated by-laws, all elections of directors shall be decided by a plurality, and all other questions shall be decided by a majority, of the votes cast by stockholders entitled to
vote thereon at a duly held meeting of stockholders at which a quorum is present. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote for each share held on all matters to be voted upon by stockholders.
</FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The holders of common stock, after any preferences of holders of any preferred stock, are entitled to proportionately receive
dividends
when and if declared by the board of directors out of legally available funds, subject to any preferential dividend or other rights of any series of preferred stock that we may designate and issue in
the future. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation and Dissolution.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If we are liquidated or dissolved, the holders of the common stock will be entitled to share in our assets
available for
distribution to stockholders in proportion to the amount of common stock they own. The amount available for common stockholders is calculated after payment of all debts and other liabilities. Holders
of any preferred stock will receive a preferential share of our assets before the holders of the common stock receive any assets. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Holders of the common stock have no right to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> convert the stock into any other security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> have the stock redeemed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> purchase additional stock; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> maintain their proportionate ownership interest. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
common stock does not have cumulative voting rights. Holders of shares of the common stock are not required to make additional capital contributions. The rights, preferences and
privileges of holders of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=572933,FOLIO='16',FILE='DISK103:[20ZCV1.20ZCV70401]DB70401A.;5',USER='JFUSS',CD='23-JUN-2020;12:45' -->
<A NAME="page_db70401_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>common
stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Agent and Registrar.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Computershare Trust Company, N.A. is transfer agent and registrar for our common stock. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue "blank check" preferred stock, which may be issued in one or more series upon authorization of our board of
directors. Our board of directors is authorized to fix the designation of the series, the number of authorized shares of the series, dividend rights and terms, conversion rights, voting rights,
redemption rights and terms, liquidation preferences and any other rights, powers, preferences and limitations applicable to each series of preferred stock. The authorized shares of our preferred
stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed.
If the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not to seek stockholder approval. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Our Certificate of Incorporation and By-laws and Delaware Law That May Have Anti-Takeover
Effects  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware law, our restated certificate of incorporation, and our amended and restated bylaws contain provisions that could have the effect of
delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover practices and inadequate
takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Staggered Board; Removal of Directors.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and amended and restated bylaws divide our board of
directors into
three classes with staggered three-year terms. In addition, a director may be removed only for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our
stockholders would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be
filled only by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it
more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Action by Written Consent; Special Meetings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation provides that any action required or
permitted to
be taken by our stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Our restated certificate of
incorporation and amended and restated bylaws also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by the chairman of our board of directors,
our Chief Executive Officer, or our board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advance Notice Requirements for Stockholder Proposals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated bylaws establish an advance notice procedure for
stockholder
proposals to be brought before an annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting may only consider
proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the
meeting who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's intention to bring such business before the meeting.
These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=826450,FOLIO='17',FILE='DISK103:[20ZCV1.20ZCV70401]DB70401A.;5',USER='JFUSS',CD='23-JUN-2020;12:45' -->
<A NAME="page_db70401_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware Business Combination Statute.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We are subject to Section&nbsp;203 of the General Corporation Law of the State of Delaware.
Subject to
certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following the date that
the person became an interested stockholder, unless the interested
stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A "business combination" includes, among other
things, a merger or consolidation involving us and the "interested stockholder" and the sale of more than 10% of our assets. In general, an "interested stockholder" is any entity or person
beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment of Certificate of Incorporation and Bylaws.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The General Corporation Law of the State of Delaware provides generally that the
affirmative
vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or
bylaws, as the case may be, requires a greater percentage. Our amended and restated bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the
holders of at least 75% of the votes that all of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the
votes that all of our stockholders would be entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of
our restated certificate of incorporation described above under "&#151;Staggered Board; Removal of Directors" and "&#151;Stockholder Action by Written Consent; Special Meetings." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusive Forum Selection.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation provides that the Court of Chancery of the State of Delaware shall
be the sole
and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers, or other employees to our company or our stockholders, (3)&nbsp;any action asserting a claim against our company arising pursuant to any provision of the General Corporation Law
of the State of Delaware or our restated certificate of incorporation or amended and restated bylaws, or (4)&nbsp;any action asserting a claim against our company governed by the internal affairs
doctrine. This exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act, which provides for exclusive jurisdiction of the federal courts.
It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as
Section&nbsp;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules
and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have
waived our compliance with the federal securities laws and the rules and regulations thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blank Check Preferred Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation provides for 5,000,000 authorized shares of preferred stock. The
existence of
authorized but unissued shares of preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of our company by means of a merger, tender
offer, proxy contest, or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover
proposal is not in the best interests of our company, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other
transactions that might dilute the voting or other rights of the proposed acquiror or insurgent shareholder or shareholder group. In this regard, our restated certificate of incorporation grants our
board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of
earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=138665,FOLIO='18',FILE='DISK103:[20ZCV1.20ZCV70401]DB70401A.;5',USER='JFUSS',CD='23-JUN-2020;12:45' -->
<A NAME="page_db70401_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>voting
rights, of such holders and may have the effect of delaying, deterring, or preventing a change in control of the company. Our board of directors currently does not intend to seek shareholder
approval prior to any issuance of shares of preferred stock, unless otherwise required by law. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized But Unissued Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our authorized but unissued shares of common stock and preferred stock are available for future issuance
without
stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Select Market. These additional shares may be used for a variety of corporate finance
transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to
obtain control of us by means of a proxy contest, tender offer, merger, or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=805380,FOLIO='19',FILE='DISK103:[20ZCV1.20ZCV70401]DB70401A.;5',USER='JFUSS',CD='23-JUN-2020;12:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dc70401_1_20"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc70401_material_u.s._tax_consideratio__mat02573"> </A>
<A NAME="toc_dc70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL U.S. TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a discussion of material U.S. federal income and estate tax considerations relating to the ownership and disposition of our
common stock by a non-U.S. holder. For purposes of this discussion, the term "non-U.S. holder" means a beneficial owner (other than a
partnership or other pass-through entity) of our common stock that is not, for U.S. federal income tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an individual who is a citizen or resident of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the
United States or any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have
authority to control all substantial decisions of the trust or if the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and proposed U.S. Treasury Regulations
promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation,
possibly with retroactive effect. Any change or differing interpretation could alter the tax consequences to non-U.S. holders described in this prospectus. In addition, the Internal Revenue Service,
or the IRS, could challenge one or more of the tax consequences described in this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
assume in this discussion that each non-U.S. holder holds shares of our common stock as a capital asset (generally, property held for investment). This discussion does not address all
aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder's individual circumstances nor does it address the alternative
minimum tax, the Medicare tax on net investment income, or any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply
to a non-U.S.
holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> insurance companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> brokers or dealers in securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulated investment companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> pension plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> controlled foreign corporations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> passive foreign investment companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> certain U.S. expatriates. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, this discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S. federal income tax purposes or persons who hold
their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its own tax
advisor regarding the tax </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=795368,FOLIO='20',FILE='DISK103:[20ZCV1.20ZCV70401]DC70401A.;12',USER='CHE107555',CD='23-JUN-2020;02:04' -->
<A NAME="page_dc70401_1_21"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>consequences
of the acquisition, ownership and disposition of our common stock through a partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Prospective non-U.S. holders of our common stock should consult their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax
considerations of acquiring, holding and disposing of our common stock.</B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions on our common stock  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed under "Dividend policy" above, we do not expect to make cash dividends to holders of our common stock in the foreseeable future. If
we pay distributions on our common stock, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the
non-U.S. holder's investment, up to such holder's tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below under the heading
"Gain on disposition of common stock." Any distributions will also be subject to the discussions below under the headings "Information reporting and backup withholding" and "FATCA." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
paid to a non-U.S. holder generally will be subject to U.S. federal withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty
between the United States and such holder's country of residence. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
that are treated as effectively connected with a trade or business conducted by a non-U.S. holder within the United States, and, if an applicable income tax treaty so provides,
that are attributable to a permanent establishment or a fixed base maintained by the non-U.S. holder within the United States, are generally exempt from the 30% withholding tax if the non-U.S. holder
satisfies applicable certification and disclosure requirements (generally including provision of a valid IRS Form&nbsp;W-8ECI (or applicable successor form) certifying that the dividends are
effectively connected with the non-U.S. holder's conduct of a trade or business within the United States). However, such U.S. effectively connected income, net of specified deductions and credits, is
taxed at the same graduated U.S. federal income tax rates applicable to U.S. persons (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is classified as
a corporation for U.S. federal income tax purposes may also, under certain circumstances, be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an
applicable income tax treaty between the United States and such holder's country of residence. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder's country of residence generally will be
required to provide a properly executed IRS Form&nbsp;W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their
own tax advisors regarding their entitlement to benefits under a relevant income tax treaty and the specific methods available to them to satisfy these requirements. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing an
appropriate claim with the IRS. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=189893,FOLIO='21',FILE='DISK103:[20ZCV1.20ZCV70401]DC70401A.;12',USER='CHE107555',CD='23-JUN-2020;02:04' -->
<A NAME="page_dc70401_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on disposition of common stock  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under the headings "Information reporting and backup withholding" and "FATCA," a non-U.S. holder will not be
subject to U.S. federal income tax or
withholding tax on gain realized upon such holder's sale, exchange or other disposition of shares of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a trade or business in the United States, and if an applicable income
tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on
a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the non-U.S. holder is a foreign corporation, the branch profits tax described above under the
heading "Distributions on our common stock" also may apply; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the non-U.S. holder is a non-resident alien present in the United States for 183&nbsp;days or more in the taxable year of the disposition and
certain other requirements are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived
from the disposition, which may be offset by U.S.-source capital losses of the non-U.S. holder, if any; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we are or have been, at any time during the five-year period preceding such disposition (or the non-U.S. holder's holding period, if shorter) a
"U.S. real property holding corporation" unless our common stock is regularly traded on an established securities market and the non-U.S. holder held no more than 5% of our outstanding common stock,
directly or indirectly, during the shorter of the 5-year period ending on the date of the disposition or the period that the non-U.S. holder held our common stock. Generally, a corporation is a "U.S.
real property holding corporation" if the fair market value of its "U.S. real property interests" equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests
plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a "U.S. real property
holding corporation" for U.S. federal income tax purposes. No assurance can be provided that our common stock will be regularly traded on an established securities market for purposes of the rule
described above. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information reporting and backup withholding  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The gross amount of the distributions on our common stock paid to each non-U.S. holder and the tax withheld, if any, with respect to such
distributions must be reported
annually to the IRS and to each non-U.S. holder. Non-U.S. holders generally will have to comply with specific certification procedures to establish that the holder is not a U.S. person in order to
avoid backup withholding at the applicable rate with respect to dividends on our common stock. Generally, a non-U.S. holder will comply with such procedures if it provides a properly executed IRS
Form&nbsp;W-8BEN or W-8BEN-E (or other applicable Form&nbsp;W-8) or otherwise meets documentary evidence requirements for establishing that it is a non-U.S. holder, or otherwise establishes an
exemption. Dividends paid to non-U.S. holders subject to withholding of U.S. federal income tax, as described above under the heading "Distributions on our common stock," will generally be exempt from
U.S. backup withholding. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any
broker, U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting
and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker.
However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to
dispositions effected through a U.S. office of a broker. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=151117,FOLIO='22',FILE='DISK103:[20ZCV1.20ZCV70401]DC70401A.;12',USER='CHE107555',CD='23-JUN-2020;02:04' -->
<A NAME="page_dc70401_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Non-U.S.
holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of information returns may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific
treaty or agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder can be refunded or credited against the
non-U.S. holder's U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FATCA  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions of the Code commonly known as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a
rate of 30% on payments of
dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless: (i)&nbsp;if the foreign entity is a "foreign financial institution," the
foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a "foreign financial institution," the foreign entity
identifies certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding
under FATCA generally applies to payments of dividends on our common stock. While withholding under FATCA may apply to payments of gross proceeds from a sale or other
disposition of our common stock, under proposed U.S. Treasury Regulations, withholding on payments of gross proceeds is not required. Although such regulations are not final, applicable withholding
agents may rely on the proposed regulations until final regulations are issued. If withholding under FATCA is required on any payment related to our common stock, investors not otherwise subject to
withholding (or that otherwise would be entitled to a reduced rate of withholding) on such payment may be required to seek a refund or credit from the IRS. An intergovernmental agreement between the
United States and an applicable foreign country may modify the requirements described in this section. Non-U.S. holders should consult their own tax advisors regarding the possible implications of
FATCA on their investment in our common stock and the entities through which they hold our common stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. federal estate tax  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock that are owned or treated as owned by an individual who is a non-U.S. holder (as specially defined for U.S. federal
estate tax purposes) at the time of death are considered U.S.&nbsp;</FONT><FONT SIZE=2><I>situs</I></FONT><FONT SIZE=2> assets and will be included in the individual's gross estate for U.S. federal
estate tax purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preceding discussion of material U.S. federal tax considerations is for information only. It is not legal or tax advice. Prospective investors should consult their own tax advisors
regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed changes in
applicable laws. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=107950,FOLIO='23',FILE='DISK103:[20ZCV1.20ZCV70401]DC70401A.;12',USER='CHE107555',CD='23-JUN-2020;02:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_de70401_1_24"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de70401_underwriter"> </A>
<A NAME="toc_de70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITER    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan Stanley&nbsp;&amp; Co. LLC is acting as sole underwriter of the offering. Subject to the conditions in an underwriting agreement dated the
date of this prospectus, Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, has agreed to purchase, and we have agreed to sell to Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, an aggregate of
6,000,000&nbsp;shares of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriter is offering the shares of common stock subject to its acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations
of the underwriter to pay for and accept delivery of the shares of common stock offered by this prospectus is subject to the approval of certain legal matters by its counsel and to certain other
conditions. The underwriter is obligated to take and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriter is not required to take
or pay for the shares covered by the underwriter's option to purchase additional shares described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriter initially proposes to offer part of the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to
certain dealers at a price that represents a concession not in excess of $1.02 per share under the public offering price. After the initial offering of the shares of common stock, the offering price
and other selling terms may from time to time be varied by the underwriter. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted to the underwriter an option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase up to 900,000 additional shares of common stock at the public
offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both
no exercise and full exercise of the underwriter's option to purchase up to an additional 900,000&nbsp;shares of common stock. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Full Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31.25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>187,500,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>215,625,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions to be paid by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,200,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,730,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29.55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>177,300,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>203,895,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $252,989. We have agreed to reimburse the underwriter for
expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $20,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on The Nasdaq Global Select Market under the trading symbol "EDIT." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
and each of our executive officers and directors have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, we and they will not, subject to limited
exceptions, during the period ending 90&nbsp;days after the date of this prospectus, or the restricted period:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by us or them or any other securities so owned
convertible into or exercisable or exchangeable for common stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the
common stock; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=496833,FOLIO='24',FILE='DISK103:[20ZCV1.20ZCV70401]DE70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:59' -->
<A NAME="page_de70401_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> publicly disclose the intention to make any such offer, pledge, sale, contract, purchase, grant, loan, transfer, or disposition, or enter into
any such swap or other arrangement </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>whether
any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person have agreed that, without
the prior written consent of Morgan Stanley&nbsp;&amp; Co. LLC, we will not file any registration statement with the SEC relating to the offering of, or such other person will not, during the restricted
period of 90&nbsp;days, make any demand for or exercise any right with respect to the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for
common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
restrictions described in the immediately preceding paragraph do not apply to certain transactions, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the sale of shares to the underwriter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the issuance by us of shares of common stock upon the exercise of an option or a warrant or the vesting of a restricted stock unit or the
conversion of a security outstanding on the date of this prospectus and described in this prospectus or any document incorporated by reference herein, of which the underwriter has been advised in
writing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the issuance by us of any options and other awards granted under a stock incentive plan or stock purchase plan described in this prospectus or
any document incorporated by reference herein (and the issuance by us of shares of common stock upon the exercise thereof) or pursuant to Nasdaq Stock Market Rule&nbsp;5635(c)(4); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the filing by us of any registration statement on Form&nbsp;S-8 or a successor form thereto relating to the shares of common stock granted
pursuant to or reserved for issuance under a stock incentive plan or stock purchase plan described in this prospectus or inducement awards pursuant to Nasdaq Stock Market Rule&nbsp;5635(c)(4); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the filing by us of a registration statement on Form&nbsp;S-3 relating to the shares of our common stock which are issuable upon settlement
of promissory notes issued in satisfaction of payment obligations under our existing licensing agreements described in this prospectus or any document incorporated by reference herein; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> (a)&nbsp;the issuance by us of shares of common stock upon conversion of promissory notes issued in satisfaction of payment obligations under
certain license agreements where our payment obligations may be satisfied by the issuance of promissory notes that may be settled in shares of common stock, and described in this prospectus or any
document incorporated by reference herein; or (b)&nbsp;the issuance by us of shares of common stock or other securities issued in connection with any (i)&nbsp;mergers, (ii)&nbsp;acquisition of
securities, businesses, property or other assets, (iii)&nbsp;joint ventures, (iv)&nbsp;strategic alliances, (v)&nbsp;partnerships with experts or other talent to develop or provide content,
(vi)&nbsp;equipment leasing arrangements or (vii)&nbsp;debt financing; provided that (x)&nbsp;the aggregate number of shares of common stock or other securities issued pursuant to exceptions
described in this bullet point shall not exceed 10.0% of the total number of shares of common stock then outstanding at the first such issuance (determined, in the case of any such other securities,
based on the maximum number of shares of common stock issuable upon conversion, exercise or exchange of such other securities, whether or not such others securities are then convertible into or
exercisable or exchangeable for shares of common stock) and (y)&nbsp;each recipient of any such shares of common stock or other securities pursuant to clause&nbsp;(b) of this bullet point shall
execute and deliver to Morgan Stanley&nbsp;&amp; Co. LLC a lock-up agreement with restrictions substantially similar to those described in this prospectus; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=1038217,FOLIO='25',FILE='DISK103:[20ZCV1.20ZCV70401]DE70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:59' -->
<A NAME="page_de70401_1_26"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, transactions by any person other than us relating to shares of common stock or other securities acquired in
open market transactions after the completion of the offering of the shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, transfers by any person other than us of shares of common stock or any security convertible into common stock
as a bona fide gift, transfers or dispositions of shares of common stock or such other securities to any trust for the direct or indirect benefit of such person or the immediate family of such person
in a transaction not involving a disposition for value, transfers or dispositions of shares of common stock or such other securities to any corporation, partnership, limited liability company or other
entity all of the beneficial ownership interests of which are held by such person or the immediate family of such person in a transaction not involving a disposition for value, transfers or
dispositions of shares of common stock or such other securities by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary, or a member of the
immediate family of such person, or distributions of shares of common stock or any security convertible into common stock to limited partners, members or stockholders of such person; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, transfers or dispositions of common stock or any security convertible into or exercisable or exchangeable for
common stock to us pursuant to any contractual arrangement in effect at the date of the agreement described in this prospectus or any document incorporated by reference herein that provides for the
repurchase of such person's common stock or such other securities by us or in connection with the termination of such person's employment with us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of common stock, provided
that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any,
is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such
plan during the restricted period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, the sale of shares of common stock on behalf of employees for the purpose of satisfying any withholding taxes
(including estimated taxes) due as a result of the vesting of any restricted stock unit described in this prospectus or any document incorporated by reference herein; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, transfers or dispositions of shares of common stock by certain of our executive officers and shareholders under
trading plans established pursuant to Rule&nbsp;10b5-1 and in effect prior to the date of this prospectus; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> subject to certain limitations, sales or other dispositions of common stock by any person other than us for the purpose of satisfying any
withholding taxes (including estimated taxes) due as a result of the vesting of any restricted stock unit held by such person. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan
Stanley&nbsp;&amp; Co. LLC, in its sole discretion, may release the common stock and other securities subject to the lock-up agreements described above in whole or in part at any
time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to facilitate the offering of the common stock, the underwriter may engage in transactions that stabilize, maintain, or otherwise affect the price of the common stock.
Specifically, the underwriter may sell more shares than it is obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no
greater than the number of shares available for purchase by the underwriter under its option to purchase additional shares. The underwriter can close out a covered short sale by exercising its option
to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriter will consider, among other things, the
open market price of shares compared to the price available under its option to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=417651,FOLIO='26',FILE='DISK103:[20ZCV1.20ZCV70401]DE70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:59' -->
<A NAME="page_de70401_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>purchase
additional shares. The underwriter may also sell shares in excess of its option to purchase additional shares, creating a naked short position. The underwriter must close out any naked short
position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price of the common
stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriter may bid for, and
purchase, shares of
common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or
retard a decline in the market price of the common stock. The underwriter is not required to engage in these activities and may end any of these activities at any time. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and the underwriter have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on websites maintained by the underwriter, or selling group members, if any, participating in this offering. The underwriter may
agree to allocate a number of shares of common stock for sale to its online brokerage account holders. Internet distributions will be allocated on the same basis as other allocations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Relationships  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriter and its affiliates are full service financial institutions engaged in various activities, which may include securities trading,
commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing, and brokerage activities. The underwriter and its
affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees
and expenses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the ordinary course of their various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and
equity securities (or related derivative securities) and financial instruments (including bank loans) for its own account and for the accounts of its customers and may at any time hold long and short
positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriter and its affiliates may also make investment
recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short
positions in such securities and instruments. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus
or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will
result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any
restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this
prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=4,SEQ=30,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=349728,FOLIO='27',FILE='DISK103:[20ZCV1.20ZCV70401]DE70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:59' -->
<A NAME="page_de70401_1_28"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined
in National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of shares of the common stock must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriter is not required to comply with the disclosure requirements
of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area and the United Kingdom  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area and the United Kingdom (each a "Relevant State"), no shares have been offered or
will be offered pursuant to this offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in
that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except
that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>to
any legal entity which is a qualified investor as defined under the Prospectus Regulation;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>to
fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the
underwriter; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;1(4) of the Prospectus Regulation, </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2> that no such offer of shares shall require us or the underwriter to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to shares in any Relevant State means the communication in any form and by any means of sufficient
information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are "qualified investors" (as defined in the Prospectus Regulation) (i)&nbsp;who have professional experience in matters relating to investments falling within
Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") and/or (ii)&nbsp;who are high net worth companies (or persons to whom
it may otherwise be lawfully communicated) falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as "relevant persons") or otherwise in
circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=745181,FOLIO='28',FILE='DISK103:[20ZCV1.20ZCV70401]DE70401A.;21',USER='JTAYLORA',CD='24-JUN-2020;13:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_dg70401_1_29"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking
any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> do not constitute a product disclosure document or a prospectus under Chapter&nbsp;6D.2 of the Corporations Act 2001 (Cth), or Corporations
Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> have not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a disclosure document for the
purposes of the Corporations Act and do not purport to include the information required of a disclosure document under Chapter&nbsp;6D.2 of the Corporations Act; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> do not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the issue
or sale, or an issue or sale, of interests to a "retail client" (as defined in section&nbsp;761G of the Corporations Act and applicable regulations) in Australia; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of
investors, or Exempt Investors, available under section&nbsp;708 of the Corporations Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
securities may not be directly or indirectly offered for subscription or purchased or sold, and no invitations to subscribe for or buy the securities may be issued, and no draft or
definitive offering memorandum, advertisement, or other offering material relating to any securities may be distributed in Australia, except where disclosure to investors is not required under
Chapter&nbsp;6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the securities, you represent and warrant
to us that you are an Exempt Investor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
any offer of securities under this prospectus will be made without disclosure in Australia under Chapter&nbsp;6D.2 of the Corporations Act, the offer of those securities for resale
in Australia within 12&nbsp;months may, under section&nbsp;707 of the Corporations Act, require disclosure to investors under Chapter&nbsp;6D.2 if none of the exemptions in section&nbsp;708
applies to that resale. By applying for the securities you undertake to us that you will not, for a period of 12&nbsp;months from the date of issue of the securities, offer, transfer, assign, or
otherwise alienate those securities to investors in Australia except in circumstances where disclosure to investors is not required under Chapter&nbsp;6D.2 of the Corporations Act or where a
compliant disclosure document is prepared and lodged with ASIC. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bermuda  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which
regulates the sale of securities in Bermuda. Additionally, non-Bermudian persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted
to do so under applicable Bermuda legislation. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


British Virgin Islands  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription
by or on behalf of the company. The securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer
will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=138187,FOLIO='29',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<A NAME="page_dg70401_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus has not been, and will not be, registered with the Financial Services Commission of the British Virgin Islands. No registered prospectus has been or will be prepared in
respect of the securities for the purposes of the Securities and Investment Business Act, 2010, or SIBA, or the Public Issuers Code of the British Virgin Islands. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
securities may be offered to persons located in the British Virgin Islands who are "qualified investors" for the purposes of SIBA. Qualified investors include (i)&nbsp;certain
entities which are regulated by the Financial Services Commission in the British Virgin Islands, including banks, insurance companies, licensees under SIBA and public, professional and private mutual
funds; (ii)&nbsp;a company, any securities of which are listed on a recognised exchange; and (iii)&nbsp;persons defined as "professional investors" under SIBA, which is any person (a)&nbsp;whose
ordinary business involves, whether for that person's own account or the account of others, the acquisition or disposal of property of the same kind as the property, or a substantial part of the
property of our company; or (b)&nbsp;who has signed a declaration that he, whether individually or jointly with his spouse, has net worth in excess of US$1,000,000 and that he consents to being
treated as a professional investor. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


China  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus does not constitute a public offer of the securities, whether by sale or subscription, in the People's Republic of China, or
PRC. The securities are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
no legal or natural persons of the PRC may directly or indirectly purchase any of the securities or any beneficial interest therein without obtaining all prior PRC's
governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this prospectus are required by the issuer and its representatives to observe these
restrictions. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dubai International Financial Centre  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to an Exempt Offer in accordance with the Markets Rules&nbsp;2012 of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Markets Rules&nbsp;2012 of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA
has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein
and has no responsibility for this prospectus. The securities to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities
offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
relation to its use in the Dubai International Financial Centre, or DIFC, this prospectus is strictly private and confidential and is being distributed to a limited number of
investors and must not be
provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The interests in the securities may not be offered or sold directly or indirectly to
the public in the DIFC. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
"professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in
the document being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within
the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes of
issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=473197,FOLIO='30',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<A NAME="page_dg70401_1_31"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>which
are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are
intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2>WARNING </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
contents of this prospectus have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you
are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No registration pursuant to Article&nbsp;4, paragraph&nbsp;1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of
1948, as amended) (the "FIEL") has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit
of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or
re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the
FIEL and the other applicable laws and regulations of Japan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Korea  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees
and regulations thereunder, or FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA. None of the shares may be offered, sold, or delivered directly or
indirectly, or offered or sold to any person for re-offering or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea,
including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or FETL. The shares have not been listed on any of securities exchanges in the world
including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares shall comply with all applicable regulatory requirements (including but not limited to requirements
under the FETL) in connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a
resident of Korea, it purchased the shares pursuant to the applicable laws and regulations of Korea. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Malaysia  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with the
Securities Commission of Malaysia, or Commission, for the Commission's approval pursuant to the Capital Markets and Services Act 2007.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed,
nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end
fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the shares may
only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net
joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=364293,FOLIO='31',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<A NAME="page_dg70401_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding
twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve
months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with
total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix)&nbsp;a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities
Act 2010; (x)&nbsp;an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the
Commission; provided that, in the each of the preceding categories&nbsp;(i) to (xi), the distribution of the shares is made by a holder of a Capital Markets Services Licence who carries on the
business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public
offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital
Markets and Services Act 2007. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Saudi Arabia  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities
Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number&nbsp;2-11-2004 dated 4&nbsp;October 2004 as amended by resolution
number&nbsp;1-28-2008, as amended, or CMA Regulations. The CMA does not make any representation as to the accuracy or completeness of this prospectus and expressly disclaims any liability whatsoever
for any loss arising from, or incurred in reliance upon, any part of this prospectus. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of
the information relating to the securities. If you do not understand the contents of this prospectus, you should consult an authorised financial adviser. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered or sold, or
be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274
of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in
accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;a
corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=35,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=747206,FOLIO='32',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<A NAME="page_dg70401_1_33"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>corporation
or that trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;to
an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;where
no consideration is or will be given for the transfer; </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;where
the transfer is by operation of law; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;as
specified in Section&nbsp;276(7) of the SFA; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;as
specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


South Africa  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Due
to restrictions under the securities laws of South Africa, the securities are not offered, and the offer shall not be transferred, sold, renounced, or delivered, in
South Africa or to a person with an address in South Africa, unless one or other of the following exemptions applies: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;the
offer, transfer, sale, renunciation or delivery is to: (a)&nbsp;persons whose ordinary business is to deal in securities, as principal or agent; (b)&nbsp;the
South African Public Investment Corporation; (c)&nbsp;persons or entities regulated by the Reserve Bank of South Africa; (d)&nbsp;authorised financial service providers under South African law;
(e)&nbsp;financial institutions recognised as such under South African law; (f)&nbsp;a wholly-owned subsidiary of any person or entity contemplated in (c), (d)&nbsp;or (e), acting as agent in
the capacity of an authorised portfolio manager for a pension fund or collective investment scheme (in each case duly registered as such under South African law); or (g)&nbsp;any combination of the
person in (a)&nbsp;to (f); or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;the
total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </FONT></P>

</UL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
"offer to the public" (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or re-enacted) (the "South African Companies Act")) in South
Africa is being made in connection with the issue of the shares. Accordingly, this document does not, nor is it intended to, constitute a "registered prospectus" (as that term is defined in the South
African Companies Act)
prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory
authority in South Africa. Any issue or offering of the shares in South Africa constitutes an offer of the shares in South Africa for subscription or sale in South Africa only to persons who fall
within the exemption from "offers to the public" set out in section&nbsp;96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South
Africa who do not fall within section&nbsp;96(1)(a) of the South African Companies Act (such persons being referred to as "SA Relevant Persons"). Any investment or investment activity to which this
document relates is available in South Africa only to&nbsp;SA Relevant Persons and will be engaged in South Africa only with&nbsp;SA Relevant Persons. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Switzerland  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This prospectus does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance
prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any
other stock exchange or regulated trading facility in Switzerland. None of this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=36,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=994938,FOLIO='33',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<A NAME="page_dg70401_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>prospectus
or any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of this prospectus, the accompanying prospectus or any other offering or marketing material relating to the offering, the company, the shares have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority
FINMA, or FINMA, and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of
interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Taiwan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and
regulations and may not be sold, issued, or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of
Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding, or otherwise
intermediate the offering and sale of the shares in Taiwan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Arab Emirates  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been, and are not being, publicly offered, sold, promoted, or advertised in the United Arab Emirates (including the
Dubai International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering, and sale of
securities. Further, this prospectus does not constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a
public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and Commodities Authority, or the Dubai Financial Services Authority. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=37,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=185601,FOLIO='34',FILE='DISK103:[20ZCV1.20ZCV70401]DG70401A.;12',USER='MTITUSS',CD='23-JUN-2020;09:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="page_di70401_1_35"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di70401_legal_matters"> </A>
<A NAME="toc_di70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of common stock offered hereby will be passed upon for us by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP,
Boston, Massachusetts. Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP, New York, New York, is acting as counsel for the underwriter in connection with certain legal matters related to this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di70401_experts"> </A>
<A NAME="toc_di70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020001476/edit-20191231x10k624cb2.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2019,</A> and the effectiveness of our internal control over financial reporting as of December 31, 2019, as set forth in their reports, which are incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as
experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=456483,FOLIO='35',FILE='DISK103:[20ZCV1.20ZCV70401]DI70401A.;14',USER='JFUSS',CD='23-JUN-2020;12:54' -->
<A NAME="page_di70401_1_36"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="h1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> WHERE YOU CAN FIND MORE INFORMATION  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at www.editasmedicine.com. Our website is not a
part of this prospectus and is not incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and
regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiary and the securities we are offering.
Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are
qualified by reference to these filings. You should review the complete document to evaluate these statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=206262,FOLIO='36',FILE='DISK103:[20ZCV1.20ZCV70401]DI70401A.;14',USER='JFUSS',CD='23-JUN-2020;12:54' -->
<A NAME="page_di70401_1_37"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A NAME="h2"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> INCORPORATION BY REFERENCE  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important
information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Because we
are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated in
this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously
incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No.&nbsp;001-37687) and any future filings we make with the SEC
under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents not deemed to be filed) until the offering of the
securities under the registration statement is terminated or completed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020001476/edit-20191231x10k624cb2.htm">Annual Report on
Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2019 filed February&nbsp;26, 2020;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020005883/edit-20200508x10q.htm">Quarterly Report on
Form&nbsp;10-Q for the quarterly period ended March&nbsp;31, 2020 filed May&nbsp;8, 2020</A>; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Current Reports on Form&nbsp;8-K filed
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020000118/edit-20200109x8k01a92cf.htm">January&nbsp;10, 2020</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020005306/edit-20200506x8k.htm">May&nbsp;6, 2020</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020006724/edit-20200515x8k.htm">May&nbsp;15, 2020</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000155837020007536/edit-20200615x8k.htm">June&nbsp;15, 2020</A>; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1650664/000110465916092420/a16-3079_18a12b.htm">The description of our common stock
contained in our Registration Statement on Form&nbsp;8-A filed on January&nbsp;29, 2016, including any amendments or reports filed for the purpose of updating such description.</A> </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a
statement contained in this prospectus or in any other subsequently filed document which is also incorporated in this prospectus modifies or replaces such statement. Any statements so modified or
superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Editas
Medicine,&nbsp;Inc.<BR>
Attn: Investor Relations<BR>
11 Hurley St.<BR>
Cambridge, MA 02141<BR>
(617)&nbsp;401-9000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=527671,FOLIO='37',FILE='DISK103:[20ZCV1.20ZCV70401]DI70401A.;14',USER='JFUSS',CD='23-JUN-2020;12:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg70401a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g201273.jpg" ALT="LOGO" WIDTH="456" HEIGHT="201">
  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=41,EFW="2241966",CP="EDITAS MEDICINE, INC.",DN="1",CHK=220048,FOLIO='blank',FILE='DISK103:[20ZCV1.20ZCV70401]HO70401A.;4',USER='CHE107555',CD='23-JUN-2020;01:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g205044.jpg
<DESCRIPTION>G205044.JPG
<TEXT>
begin 644 g205044.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@! 35),3%]'4D%02$E#4SI;4%)/2D5#
M5%]2141,24Y%745$251!4U]-141)0TE.15]035-?3$]'3U]$3"Y%4%/_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" !D .0# 2(  A$! Q$!_\0 'P   @(" P$! 0            L)"@<(
M 04& @,$_\0 3A    8! P($ @,*" L)     0(#! 4&!P ($0D2$Q0A,0H5
M(D&!%C,Y46%XD:&QMQ<8(S=Q=[.U&20G,D)#17)ST? U.%=B=(*2M,'_Q  =
M 0$  04! 0$              0(#!@<(! D%_\0 ,Q$  00" 0(#!@4$ P$
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MI1$6T+(522G(RP"[$&?R9V^*^*+;Q0TR2>"D>\\?3_.-E=<<A^7] _\ +7P
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M*W8TDA?1Z1PK1] [IF0'44W5RDGEV(>2.VS;S%0=WRE#F%9FC?;-.OG"&/\
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ME8 W0(HZ1<+I^81YE*VV_$@=+S<([BH&?RG8MNMJE56S1&'W$516G0?GEBE
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M404[(Z>R6Q;'J%7@W/$@O R5@M"B"+!E&JR"\5Z/+1Z/ !RT=CP < '+=7T
M ]@_$'U:9:6?,#W>OSXQO7N1_!TY]_,MRE^X2<TIRVV?SZ;<OZZ<"_O*I6FQ
MNY'\'3GW\RW*7[A)S2G+;9_/IMR_KIP+^\JE:9+GZ?/^,<QE^]*?[R_]HII2
MAU7_ ,*!OX_.SRS_ 'ZGIM>7[TI_O+_VBFE)_5@$/\*!OY'ZOXV>6O7^B=(
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M09LVR#=(H\)IE =,A,P9CQA@/&UOR[F*\5W'>.*+#NINT6ZSR*$=$Q3)J01
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MA1]PF%\*(5EG(LLJLIYTZL"LJX;.X8T.F]4(1O&D8K(/07\J ',J\;"GWB(
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M0 @&C1IC  X]N?M$1_:(Z.T.>?I?_(W'Z.>/U:-&F,YXXUQQR(#Z^GY1 /M
M!X'[0T:-,9SKCM#\H_TB(A^@1X_5HT:8SD0Y]/V"(?K#UT ''I^T1']8^NC1
MIC.   Y]_7\8B/[1']&@  /;G[1$?T<B/'] :-&F,!* ^OK]AC!^H! -   >
2W/VB(_M$=&C3&<Z-&C3&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g427184.jpg
<DESCRIPTION>G427184.JPG
<TEXT>
begin 644 g427184.jpg
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MMKP##?5 !BM>U[7"]MEPOD("/[844,&#!A10P8,&%%#!@P844,&#!A13%GN
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M.L1KI;6U0K(C:V+88/(@[J39AAOV YCE&4QOI82N 7VY6W".WFL&?3:]M^%
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M:#P6ZW.VHJ/4DYI!O]9*+[2DM"LDFG30)E$!62E]M=A.%RL*7/,1R2Z<V3I
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MWO81&PY7V7YAMFNL6_W+=^BE[MGZ+P]=AVACQL.5SLU@BY4N?6"X!%RD7=8
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MR?)-(ZA,F&NR#DV$9H3H(.*"" )8" Q"\;'XS_F(;C8.-E7N%P&'C(=8!W
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M.Y=Y-B<@:2@#P2>C)K#'&NU4&,81 9D;E01F:HAJYS!:VL(6L @(ZHAZFUK
M'(>"6T:(M:[@JN(QPCKCRG1!&.&( A'6'DO>*&*"&&"+6$0BAA"$;P@  US2
M8E<)-->4#S23-8$%H.FB[!+O:BE!E$B^4^E"4VM+JA*95\Q3:J:<U6BZZBUY
MJ!HYFJEN)%-34A(6V\FE5)$8"<"P2FK"INO0X3].5*J:B+M?G34IV-A8T(6H
M=2F2Z$%-0FXT*PH]15B3)2'4MDH(SR_6=V,Z)$.OX\M3H)Z>$,9(@0*RY)Z>
M<P-Z+QA(5UZKFQA&)/X+B0R?_*6<$AGO83=0?D&S]_>1^]N\?1G(<$QHTA8
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M:<2 [3! \4Z!<BZF=AV>&:9A/L&.MD!-C)\LMZ]R9T:L[N.K>7]E:, !UW;
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M,B)\+%PC$P(=?2O?\6RXBBT_N-[6&P,\ ]H+9XXZM'^D5&-ZJBTG^R:\^/\
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M1IX:74N=*F#7%S3.+F03 ES4UK3),P9<01A!.E]H81F2H]74FP!'#KP11!K
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MOV&!S6OXKX^V#AEU*,(;:/94!'/.IT_GSMZS<P#GR#FV8XYO-?D_X2J6/NK
MW?&-@8-@QE3+K)<#'LPKV#'TFK;"27GQ:4CGM <3>O86T8M):&VMH[UU#+*]
M)'Z&T YT'+9X]O/COBVC/I(6AOH]5RARA"T5)GV&8 (#M0K96N ^T(8G\AX9
M!3B#_P!WXH&0#^>:8O\ ^#@'9GU>+&SJ6<+ BO=SEFTZ:72V7$J1RBR,J1/6
M-339RE-F:D!%1FS$!/[6PF+PPE3D?&EAGB$DP,CC(9F.#6KTWRJM7BUF-=6K
M"%!2J+%,*OHCQ A(&L1"@Q(D582ER0A"BP468$TY=6N]<6N1X%4@7OK/#1XB
M(<,1;,C5>&5J("4F-'@PH*-8LD%:T@J(3B:5S)&CEI#0&82L5!JT0&)DF88E
MEXJ7/>&?,D2HI<N;/ADBB<9%)E3)DN".9#",,$<<$$0A%'" Y$5T<-(B$( B
MH'6O*(1$1I8^-FL.8W0PSW^[<,6RYND 8C<)5=%K! )5(/),1,5J8 1]F'"1
MOLB*/L"\ RA)A*XL9<6MKA%KP:@0CW/IF9W>=+'_ #[,#_\ 5C[>/C.W#6%.
M]DU0,9=^K!?!SX ;,,=COA3[$Z&JD9]>*Z7^+0)3&'?)RPY=Q-*FLK1UTA #
M\X:M 6MF-+GL&^X@'REYA"^8<PX[.#1VT@@& 1H164,[W]#!Z6';O[2\WM8M
M;#I,S^\Z#9^WL8](;$X/#E?=G@],Q/ ;"S8 ZU^8/_ZP>C9[F,3I>CEO2RJ[
M/MU9S#.>XY?&V5 T-U,,UL5Q\_L:!F1[^6&?BI57E:/5?P  &A59  (M],7F
M&0B([.TW-Y\AVW#LI6CY7P!'\@VL( (VSIF\M]M_:;G#IZ>?%I;TS,[<S8-]
MKKT>[9<>U@YC@#28GB/T&P6 +_F]'NY_E9F'1;&!TMQB".ME5F_JU8S;WAWX
M^5J4:'*F&/7BN8!B:M VAB>^,><^4TJ[2M'ZO<.VA]8 WC>FKRSRR_6;.V^^
MR^_'V0T KSJ_G(U>#,?Z6SQOS;.TUQY]WBQ9^'27G!;UG0;,KK\87\:9;?OP
MGIF9]_H-@#_/TSIOL3/$-A^YCVVHWN95<  \6L9-/P=ST=IVIG\L5R9<GBL"
M9($AWS @#Z-U8J&@->/K)5=W;*;O'=#8;_*;9UVV7V8YR:%5PG#-ER:,U8FS
M"TP))F"73MW3(R\X9<$T)4^&!(&*5,&5,ES0@F!#$,N.", U8@$;.0Z3,_O.
MECU+LS\6!YL=.FZ0<Y-.KIP&M"8%:49*AQ8K<R "HRDXFG\3#$*=&,P(@)A.
MU]6789HP:GJ B''MLQ^Y]+*J7Q[[6 TMA0'G(X%R3A2]IRJ3].:YDWV+ G@&
MG$'GANK8EM'ZO4^=*DRJ(5=BFSXX),F :<NV7K39L<,$N 9DY*ERI>M'$$(Q
MS9D$N"^M,C@@"*()1]'#0W>=+24ITN5FN(S4%2(129\J$A-G%&R3-VBFI9..
M6 P&#TZ7#*@53MYD 101%"@\3!%.G2/^F9G#M9LL/\_S,_ "7GU#_)A TF)]
M\F;*AYOE['XLDS[@8Z&\-_JW;U2-G@(L^KQ#]E<7,5:ZRA@!!6M8&K!=U1$)
M'?9)4=360KZ"[>CBS; KXM%4:+:59A &J\8APD0ZK$SCH0@G6C 20M9:$Y4E
M(7JJ1HT:>/O;R/<6=\NU9@8M^T+= YWP!3Q^7^@YQ@&>8I1CFWAJB'\]QQO3
MTS,[>SY8]2[,V_:S9T^8<'IF)VWD;!;^[T=QSL-@[6;NOFQ\%J57V9?R#N][
MR^8GZ*\43*!@V?O1DI]G2::+&GS[#(&>XMG[5F,K[0^9S&UKB(7W83T/'V%_
M6<X]^U*,;AZN>P#S7'&]0TF)UK\CH YP[>3-O7VLZMPX/3,3MG(Z7>]LEZ/J
MWI8=&R^\=V;4JOLR_D'=[WEV_23Q1, ,&SEECW6\>3*6B?0]?G><XOM88^]P
MOH>/NUQ:#BWCDF&,K!<;WA ,@Z<;U'28G]YTL,Q#-=F#LMS)F.(Z2\Z(-7D=
M+N(##?M[,_10B B'RKZ?AM":E5]F7\@[O>\N?UFO%=]7/##8,S)_H?(4T*58
MSR.EY)LHUEXT5,RPFES!=.GS94Z7%?5F2XP"T4 VR$+@(8^CT/7T-K,]Q7U0
M"W:LQ>X"%QMJ^>^?CQMMO:0$U 1$Q&!K2S()I264 QVXCE#-XL1$8^*!/C"7
MK:WS.O':WS0[ [@=)HQLY'2[;OEW$ CS?K;?/GP"*L0'C+!DXU#+!P#JG?//
M=)Q7$Q 2SEMI 8SGAMPWTT8%/7V%O6<XMH[4N?L$ MN\WAO@&GS\$?H.<06V
MV2S 6W#E8>K;T8WF.DP8"X"S9=^A=CMX?E9S8 TF9^]G2_MY'[?:WW!PU*K[
M,ODU"_D\_*UHHD$ $;-[8SQ/3318T^?>YG.+9G\K# 7'JU?-A0IZ^Q'Z$'%T
MW3# 7#FO8<;T],S.[SI?V^F?BK &DS.WLZ6'-9=F#_\ JP]W#4JOLR_D?R\_
M'2A44'P$N<O-4L7.\FFBO0]?FYG./??Y5F-V?['/G'FP>AZ_+7Y'N+/=VL,7
MW_U/1C>OIF)UQ 6=+L%L^WT8]/[5^[[6%'28GY^LV"P6S[?1YWV?K7\!PU*K
M[,OY!^KE\\< 8F.J"3)\3EOW@<]-+I3*=Z<K(YU0;*V2)EUE'BGFC2?/E%Y,
M,2D5@"*9,$ "$!BB"$+[8A  S$,;?=NBCV\6*JF6E6FJU,&U6X]/5*HLIG2J
M;G4A?63S33&*N+B0J/%@N=SLY4<+314E,4YS;6R<B4:(2%Q++)RW&9/3^)NO
M$UUPE4")L0$85)51)(F@6(S R-57(S@B"2*?*"8(C*U=49D(9W$<LW:A.@AU
M@'6RBCN(01Q!"%Q'U0PPB$.0[QR#,;!CL+/BFKJBFKQ"0H("BI"2"RBL I6E
M23JJ0A:2SI4 00133&0(H3PB<"HAE%)F-4D%)!F"H$.Q!(+TC]8'!_IE)*:'
M*,4JTA*ZLBE*NBET9=:TJ.E+C4%+6:*0R%M3D/)TTQ6'2CJCG0$,CVVGIRC+
MDE5B(ZNH1=(43T^8.3SM"1,*M!VTJ:5:*N,:AKW@62:]1M"BIT>09*(Z2DLD
M[VTW'8XV"L5#;:&YRX' .2B+HB.IAA75S3?.I4TU*$N\X@M)*J)P$M1)J7:X
M^92E#M>9DG0(*A(8(3B:=$M'- HH%!F2P-$S RS)<8X..E0:T-U(K*6J29IA
M,/E5$O(.'4^<83Y\L[(DGDXU-)*).;-*Q38)1L@=D3BATM,BAGE#4F:7,2Y<
MZ7' ':&T*X5%2HKJ*TQ%%4*$2J(&U(JWAG7C)U>XBK>(GNM50UE/H%7@@ !+
M#5U0 M;!&:0-:2"_=)'<F3@L&;&GZ(%+TRN(5R*1.26=+'Q=*;3@5R**E";5
M(PUBC!4:SE6GV+Q@U.4Z?)Y%F&5<RHF$N2GR3:R01RCL6EUP*3>$W@M:&MLZ
M<-M-84R7;4@W2RW [&#1"J<2H?;"1*;Z>M :J12YP'TLZ802J<F*A%*.%T%0
M@3"9T4<NHQGC)R2_LF3>VMZJ^KJZL6OK9AJZMKWRV6VY!GECXTU92U@B74T@
M^55DTW ,PHH)<^4HD34L(XY8S"YPE'/+3X F2XY8Q2IL0!,@C@$0CA$ B+0K
ML-RFL16X.' (40M!AH)5"0I*PI)"5:RD@A]8E6,Z0U:KD_:D.%JB @$$+4 E
M2@009A@6D PE3Z"!2$B1)DH-34)E2Y6#BY,@O+U2\F"3#J%RLN26D0:L :L@
MO*E2)4-I<F7!+AAA#Z\( A$ " W 0N ] X7'#IR*&,&7P$7FQK;.*==_"F%0
M#<(>,!ZAOC.<8.O9/1B\W%NJ_3\K2OAY\81/!'^>'_Q$TH^@^2=-/OC11I!4
MRM#5KA4%KISO=#&:95L,\HN%X#B4@S2SMC> +I8K%:5/5!4H282X5"4=*2.P
M"IF1)E&((XHV;-+@HZ?H2C4-<<-6GV^EVH)5]E#2HY4!C3IJ=,>=,%VE,M8D
M2@2)Y>:N)2$N3#P&H910@>4Y&H"6GI1B<F#*WV1+W:XA>PC#+F1 '2(PPC8-
MOJAR&PV$;#91G0 %QUA#+9!%%:XB&>J VV7N-@MGSXV!1$P3, 8Y8@!\!M 8
M'.ARS.^&+9>>6-(FJJ<$?1RK"7.D+KP7)*T:,SE-14BK;;!5.75L]4"HK\4U
M%R(B3*1HUJ7,&J#E1$T@95@DI!22C&"\V;,(SI)S)7MP5-"'JITK.FCZP7+4
MQ=[K<4LA"5)0REE-=BNRUN>ES9Z?.3)Y-72#;!;I5!>$P5)73TR48)B7FQ 0
M,D)0 GRXK" B(#E<(8A#J$0 0 >8!&X[0"V> 9TL-L7/;(<[;;#:PB'\U\-8
MANZ,G:;8@ [IAAY*764\L3N#^2C5M%W193-&)*=B4F/-6>8.M6;1J(TJMYGM
MD4U*9C+2&"VDN4292*BIQ\T7;Z$G=METZ5B5%Q4 RH&YD'&P%Y+KL?D$Z6-O
MFL]X01" ;-H@ @&T+B(@ 7L(@.6%XV"X!?,;;AV#ES<^W$<%RX.WR#ZA2%S/
MSE3],&#!A24,&#!A10P8,&%%#!@P844,?E-A&*&$ "]IDJ,>J"9#$/F#'ZX_
M.9'J0#%< M:XCL -^\/;Q#*BE7DAP5^E4B2JODSU$='6I917TKVA7Y-3G@]:
M=$D2K+-;.E<Z*V':>/&<G:.<#W+2%]H. L2.05'>56$62II<HI(29989$9;8
MJ!P.U3S-&M(MB5%0J!NL[5$GH[*]*VH:E''&R*)&F5I1UFK$\*9,8PZ4*:?2
MF:R:7U.+TQ9BL1))4:\G2U5)[3(+:GEDJ"=-I:0U+WHY:H-5(<D!54I"]1I^
M\ 7R!QME!<<#5!Y3H6\HK<HD2=*4419*N!Q909IU.**3;=288,2SK969)3H6
M;I<Z-C]FR2K9K?3,Z>-O&HC!34\P[D--45IU4G.S4^H:<A$%$^6-+<+6GR8X
MU(VF2S).64&6?AG1DYTJ=%N$98?5832I4CB-4I,Y!V!D 5.02P8-[# !\99@
M[7:;OGO=L=4-"U].UW:/2T1=;2FMG1XTIVM4JDK%:[5-TB:=**)$6LNMI69L
MAN-MSK+5J*YTN2;)RVJO*K:;H(R::4D]'2DD#!J>:C*-\%[I7I;!(4WDL2@3
ME074^Z4(U3UXD[8"-14QBTD8Z>VWI6.CKB=#&/$F'I :4ZX63Y]07G$347*R
M6JA1PDU=?=ZF35TF?\CI T/4I#-,I]8Z6'B]132T28,\J_FK.E/4VVPC%PE6
MI' K#"OF$.&7,B5Y26)J-/U1 S#*&*"_3R]*#1SFHRPXI=?:+3D)O$"JHNJ\
MBI[*GIB.FG50VADSZF=D+<V02*'%D@=22IB?,@E&5(F9)R1CGRHI88)6H,P=
MF9T@X*W2\(E]I?$8UY-O?.9EC/8&Y*-WKE1RMR^09+DI>U&TIN9,1](2G:NU
M:BU77YI8FAUOBE%"#VDO46^X%!2DMF>E$5.>S!3Y4^% 48V^B*A<RC%Q--2(
MZ"NE@977HA+5:'A"PD)?*+](5I+K2\D=WHRJC4-J6QF_+;,",6))S!9,IPN1
MHR%)L$2,M3/)R48+KBFZ")>(TIOZ>6F+31K2I':9%J54Q1-U#<5-2:#2NGRF
M]%HVM-1HDWRX%$D5+&BDDZVR+;42!V4N%34^0HS#A<HF2CIJ;!*',DG2HT=E
M=%DK\JMU+R)"8QV]4DQ*7GF@-M526.ZNQ(4!QN)#7U!.66VG*!@^4(2XUTBG
MQP*4^6G3()9V.&3%B'2&$GP+.<09.X=\)9RI0HC(;G>3SE/^N]@S$J7:+&FW
M(J0\5.LVD4[7,T%JN+#>T1-MU%5V\F'*?H)A\KLULH"(DIA%39Y(L"BQV6ZF
MT26($-]D4$ZI&8(@G\?.Z1_Z.=>*?5$TC*P,-J)B5&IRWM4!J.)A&8'K4][/
MY76V@M,)IH9&4QTVI+.;JPMMLHAUN;:Y4]Z4Q5V<<4(FHCLTEQAA%D+G:45
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MMV6>["@ CD("&>T0O;JRRN.T;X=UVVT;-O8J)MW)"R%Q_> ^Y:VX P=M]&P
MMV*B=7:99'_5Q^YAP ]G@?+Y-V^>QN5G"3?44VSHVN,M@^IHEA"]@'Q7^'6&
M$M$&X?$.'=]M]&P-A1#^TJS^#X7MOHV6^=43[3K-_P#L+C\+8< GV>!\OD;+
M?YS8(A #I6V/D(#M@-S8T:((".Z(<Q'.&V8^/"C .60> ?;N/M8=R*OHV#F)
M5$YOS&6@V9^Q\)$K:-P@.H51+VB !%(60L(@(!F,C+/HMO&UL. 'L\#Y9W;C
MM\YLX1P1J+.^9W<SG+>ST:*("([-N>6_G'X99ASAA;#81$!V97OS@'M8<\VE
M*@<I 28%XLCQ+,)&5"HQS4I5FS1-!K!,XR9*DC+CBRA$8H!BA$=@[@[SMOHV
M>Q47[3+0_P"KY]7BQ! ! /#00X!8KF':1EB'GR<K77$NX5C(@8X!FSDSB7(*
M-%M$.=A&_1MMU800'FMX!V\V?B\&5\.\[;Z-FWL5$^TZSU;.(]SIP@J^C8/Z
ME1/M.LA_J^+Q=/L\#Y?)NWBCA-R@<9)9P&EB=\R_02*-$L/,/B'!8>8?$.'>
M"KZ-F\JB>!'6>?HD8.VVC9%^I43*_P"LZS#U_I ?R;<. #/P\#Y<LLVW_3M9
MPID-11Y0\Y-+IYVHT00RV"'.&>Z^8#L$/.&[+ -[6L( '7\,QSZ+VP[OMOHV
M[!*(H6YT98'H^H#X]G3G@[;:-M_G1%W_ *SK([.CB+\V[+;B\7'L\#Y=(%D'
MP5Y2;-P9#?\ 31KK="Z^@!F%UI) ! +@'RQ+7$=EA"V68Y@&6,+T@J/UD<+^
MTAIQ^B5;ZOKSQE%/2T51ICI!IE+FK2,B+"3$A+1C:&>JJSSS-76K4PJL/9>=
MR>SWO"ZR"P3G@74HDX&I*>*I*5#)TDO*:Q9+@7YBJB FQ%TQ4D30G=N"(Q\7
M,GR894L>)"9<8A -41 ,X@ 75  9WME%$.[+/X>"V.ULJL+J$2,N&848K2@$
MZT0!+1$Q RH2X2P2882H!;*0I25 NXXM:A)K*4)6%("220 D@N@HF%I4"&6Z
M2SA0209,8 V-H\Z2K?8U63E6=&.N#QTGZM+!RJ"-46C.DTWV)31AU)?%.68F
MJ9=**2JSM$LRX6E4=#6%E9.)[ =11P2)LM>DQ+XJ8MTAE<C1CKBQ42L37]!.
MNK^T@'2_WV[Z:Z2[0TBTML4C1G'44T5<)%UR6.<JJW3S":S5=JBK*#K8D%+G
M7&O 35IY87% ZI90O.CZD0N&J(!E?(0#HPH##%F @-MX6&V.[5;=942>!@ *
M4A10E5:".]A 0@)%9[F" @A4%+0EZZM9)*8>IPQ4(8;OD0D)*02F 3W1)4H]
MYG$)(/"%U#52Q#KUXU6Q172C2'4B:.1UQ+1O1C;+H2ZH>C^8?IB?5IS-(HO%
MG"G:+!F1&=FNX($UZ%37;^IALU+E*U 8D&F\LR>=YMQ+)5@$6BSITP'%$G5!
M-JH[TXVQ&,DL4TP%Q&< 4VF%6^HIKQ*$2TK2ZT?DY*>G*N=/=X.2)K/$BO2S
M;?@C4Y<*!/0H+%(C"&T0"^RX@%[=>VV$ 88M@PQ=5AQA"MBL02LI@U5XB4!:
MA"(48B5!:XP4%C5BQB (I#)* $)0A,J5=0A+"0J)&(0I2DI*P4ZI24IAD%,T
M0P288/=!7=%2C3HFHG&$=L-Q)-GU=5-)B"CIYE3<$TM/7E$P23BQ:>?6IQ,1
M*35<Y-E1F5*:5^1IAV;/CD7E10#CO\&#'5$DDDXDDGE,Z<T!@VR5#&#+_P!&
M3&#,1&2Z[!N$>UA7;OW[L9SC!UVW+1B".Z6ZNJW:TK?VL:XG@C_/#_XB:!NW
M^2?BHR/2;I=41RUE:+EE4;=U=F6++34%GD6G5XA2:"BM3BKXE*BK4M9,J#E0
MST<A9;4Y/E%W0TTYUNE!D-$ZW"K<,DW7.CFM'?=+>$>J$ZD,ZKHKP.D6-4^>
MXHY"A42DS;1UE3D'5_6,TZ!DJ)%1DT346\29!5*0JJ%E5_D')/7CBH2GD^R^
MR9RM:#+U4.>S,,^K/VL*(PAM$ N.^P7'W1QF[ 82D">7(8!]PGA3(*;('E?Z
MVYQ/>](#6.T^%C578S'TZF^\D1T$'8\D%$Y1/J@RBU$9G.XU0U?GPUH1VTHZ
M[LI^F*:361.19E.TU.J>3AA:T!<2:.:@DAO9LI?"1&6VZU1;@J25/MII/I9;
MC6573HX%W"_JLPMILD2Z*37&VD*S>2:-&7&?=:O2P@M2";P+RT<L6?RJ4*&$
MZ3'+V PWL PWVV"U[;!&WB"^.5@Y@_GV^/%)!#:J1@) X#)R2?-PQG0%$9)Z
M.9N1I3RI!4P6#PHLM+//!SE'2;JI$T>US=+O%V484FTE2V<JZ3I9JGYZ6D*9
MA(*58<#?=E(Q45^ 3C74)G8DER294"*MR(7'4?0]/R:\Z=.%[*[Z36"CN).3
MCK'?AZA*JYUBGZTX:B2E57JVIT^D"GFJD-=!+,,P1F4X4B"#%+/RH)Q1:4Y2
MZ!>4:\(#:\(#S7"_/L\-\+B%B7U4B8,AA)F&YN@SQHUCL&S#>_G]= +V"^VV
M?7@P8,*8T,&#!A10P8,&%%#!@P844,?C/N$$-LQXR58!&UQUX1 -U[Q6"UPO
MSX_;'YS)?&!"%[:LR7,V7OQ<81VVA:]K7YMP[,**0KH^B_H>OI57&U1+27>C
M(JJ8G*R-4IVLSD\K.NI;J5'14!J.]UKI9_L9=:ZTNFCM2:IL907VJGPI#9,O
M4W*DQIATHAQ2-M2N#8I!+5X#@UK? ,U86U):<;'-)M%5!'=B856CSP9B+/65
M-@*#@(H[(?;@<+E@F(:H1FNXHN@U'Y-<+6)D$V7WSNX.5H^A>X$ML/)ZQU(-
MK+J<D#M47B\C^N67'B\'_.8K.2'&[%QL4G0UE<<2>45##-221&<",04%!(.]
MCRB\AKU(^"B4W?3MTJ->8Z:LE_N]QNA11VPQ&,G*36IHWU-'JZBIZ0W2<MT&
MTY+A.FJDHKJ6D1$5#B."NQ42"6H'8HRYA'R!))=9:3.D%4P 3CDTMF1VYAF?
M7(.QCD00S9/T@,0Q8[F0N"OHNWF8TF&<K948XA-(R?*/9/F2*3II5V(TYX)]
M26$SX2<AE0P4F;['>24F+R"DTDC8@+4F)12EP%%#4NP2WXN3@S]'ZIS><:(Q
MJX/1G&598<396%"G$ZE@1SSR5#2]!>;.6DKDD:3U6!/AI&1+JR"H%YHI2LHJ
M)PQ(@C+DI4GXF;P2K82%MV'GS5<W5).<JKVWGE7JUU%7,JQN-HU 1I)IW2U1
M[*#?7E%N.%]0+C-5)+?3E!"36\FHD1@U,$5.5W<'!>E(%5+CAJ2TI:05<)Y8
M.FB]'H23\E2S3O./LV8:[X3W\2,M9SO175E-MU8=A=..J3_I[*1VY9%44X5V
M?7[H'6.\M)RQ,LYAILXW2HDS:YW8NV9?%^?;MIL%*T%4)I4^I0T*-:352J8K
MS$=RHNM:H:.G4:=;A6"QRE:325?;P)CN8ZVTYTJ8WFX34(CR6A0*J8LEYYB1
M.E$QF$@P5'X/K1I6ZGKK31:ON18&F"I2=_K5%XC%,G!.9KZAGL<Z5?;N5#+/
M,5 -&:LH]'R$)QMNU?.-J5'&O.1HH:,>-)APAB#-X+!WM8[HXA,TD$V>W]'^
MH2:_23=)T/0B,1F%%J,A/DBVT%T\K)KM1DH^01IS87YZVL.D\L%%4X<4)QZ,
M(9$3WZ&Z*270NK-8:GI%3*CNZ56 F@PGVT^%!(6)*(K);OJ,[CZF26BJ,FK"
MA >GU C2T\JL3S\Q#1D@HEE3DXC"2+IT);!0)VL7\(9L"[!QD&9Z1VP49CH+
MX%Y-CAF^TOIE*X-.B22HI)Z2MNB:72"3#)24B<FL44><# 1&6B)D^>GRVG!(
MB,');'3#I^;!! (GIQB<5['" K"7UFPN"2I,RJBMA]':MU7>B>RD:GR"U66[
MR=-E)O):6P)M+SA0C%'"R9:B83C2C2AOFY":)F41183:G*29$B.85GE)8L&(
M"0[$SEY,-F&(8T:RMOG]6["D?2/P<U&"K5&GSF456H5./1?I[6.-@/IM4Z76
ML<6&#2%,H\#>5TN>SP++;67TE((KBBG*DHU.(KDL11#2<G#"1@TR:X("A1E5
M*&XG[4*:F$:+N:AY$@I)5-%E32FH9;U0673N:A.I39)EPH9NE+'J.K-1OP)Q
MR46<*>F(1AZ2UY0DJAE6EKP8NLH.Q,Y&?(/H$\:1SM\Y?4*1UE.#<I1!$[3J
MF\7FKKKUGR32ZOSTQ@E%&,P+8JVV5$"(D&B7E$":K!6)QJ)I.+PPDH#I-+AD
M2996 W(-8H@\%[3U J91JIY>KM2YBW1U<03Y.*6C4R2SSA0FC+"4UF>HN-%9
M2:Y2#<+R))(HY$])5"I9YE2H=ORY@Y.FG1D_P8CGQ-MD0WGLH<LSREXL/)3C
M!#JPPPWOJ@ 7M:]@ML#(.H-FS'+!@Q*2A@P8,**:QK5E2"JO_P M7[_X45L>
M0 $<8&9XZP_ETT;#$-P^.S1L( -LLPW;-F/84J:G0*].GXES9L<F6I,QTITR
M=+AABF2I:@AGB<<V"&/U$4<J&>,R"&+U,44(0Q" "(XJU%/B471^,291D=+>
MN%S$N69&$&134 AB,0A.$ N7B'(8[9B-K!G%M'W'0U?B[ESA>%-O5J-5E6AU
ML-6$*J5BLZXJW'Q%<P(:]35,:&1K:I4Y9P#3Q?2]<JW[X)L1-B0($8U$U_C!
MC5J%5V$?B?! "(1K/P2R6<!@YPI2M1ID>L%HHL@C#YH=@@.SQVMX>C#DF=%,
MA@"6,<=X8K"(1"(; #J'(+C;>-@SQ;<*_$J5 "L010:65<!$+VNS*:[[\Y.+
M*PVM_);.$OXF-HDE_E>E56>=;9QC+IM#N#(=0E#?9G?,<L\>O5_3)<*LHU8=
MIUDMZZS+0#S'Q<C!Q-LJ>-V7H;OW4JPJ)%LZJJ!!2DP[3J:@ 2DETJBPR'4$
MF3LQPRJ_-:9&/%0ZXA88;",0W&UPMF.P>:PANR"V'#-V.*T(ZPYQB%PBBR]3
M?.PWN%N?FQ8^3?B<^CR;JZFDO5R;JB ^K:-/X;B&\=0J&T<QW<U@N YTG\ 3
M2A/U0@TAZI3 A&]HFJQ@ >>X0E]_M^+'R5:TFW/BDE%H1B),.(5T;-L'SFS9
M_5HT97P2$ U""6 !>OU+8D/]N.#/+*33E7Z0(AM!G$ C#G<1V^IV=%MWN8V.
MG1#K"%XOF@':.V]O%8+C_(.)\B/ =TQ)  0U[J3& ;HFRS YOV)>V[+FRMF%
MQR"1P+=-I%K5RJ)%L$=9N-',0WY2 M_/SXZ>)I"NLIVKT;$-]A5O)O@?/DQS
M&C2]X4_6^%D/N^I[I@\.6Y.6>R!XMK:NJ(C$ PAK (B.5MX7L(#>V8#LQ*'H
M5O6H:RE*;75B9E38K?+0PHKB.S(X(T<YQH!"VB<Z9!$*F4B@BCGP2(9FLB0R
M@@UH2\Z47A=T4X'.F<B?(B,5FJ'/+0398SY$M$:9:;.D0QPC-DRS(%9HR(YD
M #!!."7,BE"(1PPQ"%A>1#HQL&G+>:S=:YE7(HQ=70FZ4)A$2BAD%#YOB9\\
M9G8@3)YV8(B8G&I\4R.>8BBFSM>X 'P=^;VV/:UD&H5" *_%C1$J$:/"B0$U
M#4U6C02L0XBHZW,- 0T/4*^&*DG@E_;W#N/;]D6R+2M&,;.@P4%)J\"/!CJM
M 1 !P$7@U1(::NE@M96.$$1,/@0E0X6&VX1$!',;^'QALMEEU98+C81O$/4(
MY9[^O=AYH:-S5O<5UP#_ (9#V^P^?"#HW-6]^WK@Z+Q)X_ZGCQKBD?UH^4*>
MXB*@  '"4WW3< [Y>20+,KCSCXQ^'-@$1':(CUX>:.C:U1VKJ_\ ND_\#PHZ
M-S4']>U_9;YHA^!].P;X<4C^M3\H4"*@/+8V.38RR;SQHS$1'9F !L =H6^'
M@W8+C>^SJ^&_?TX>;Z6UJ?MXX/W:?NV?J'"^EN:H[5QP6_XZ?S6']1;\.*1_
M6CY2?KI!&3+'#9R8,#/H$FG(T9C<><>;P<VW!<><=G/?^;9UX>:.C<U=G;UP
M6YM9/_ \*.C<U+6[>+X?X1"WB$GAQ2/ZT?*%*(J&$S+<3S3R/T92HS(!$!WW
M$!#ISYO#A!B$1OLYNC*PVYL.MFT%;<MTD4$%A;$L90E%5CG:Q+CX9Q0^GE8)
M< @4U E10&XXHP& 8M>"$88@ 8@'(1T;FH/Z^. >N-/'_4MV(FJQE.R1(L>Z
M&+ ^0@TA6AFF 2"&#R9IS&QS])HS&X\XY;,\ [[;/AS98>:&C<U0V+K@_=)_
MX'A0T;VKO7' -OZM/_ O%O#GV6O%(_K4_*%'"(( ),@V!V#D\VWBC,L\K7O]
MVUK>+IV=&27'G'QCAYOI;FJ.U=<%KW^:3[Y;,^PO'EGOP>EN:N]=< \]XT^P
M_P#X6'%(_K1\I/UT<*G:7;!BWCF^TE\9/1F5QYQ\>"X\X^/#S@T;VH 6[>.
M?\,@'F[#P>EO:O[>.'JUT^W_ '*_GPXI']:/E)^N@Q4N[DY,1A-WYI;RV.%&
M9Q".L(7$-F^P;.O+X7P@W#8.W;UA?QAT[^L,/-'1N:G[=K_AB(9]?R'GT6M;
M'0)%!&VHJ#D*35A;@@1E:00+Q01$M:;*C2D\\,<[6*" S FFYD$(P:D(2X8
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MK"5UV0Z%9EM!4<Q6,K-*N-0:R$=7RTXC%K$ITA9-$)RE)FDX@ 2D<LU#&6$
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M%-(C+=AN/-22'NJFE'['IAY(J'OAY_N=.%[JKI1^QZ8;>]%0\7T0AB-X9$X
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MAF1M:)Z\@3DY=QR'#>0TI'9! AY0X8?#N4[L@#A+DQVTF'!KMB.$(@;R$(1
M A%VG3LP$,MI;98>:^%Y+-GO>0_M0G?@V(=%S3RTL64+L04_1Z@=TU(HNR'R
MV5(RE5*-"WU-9=360G2I5I78D1%DIJ>WTQ?5W&EH+61%10<B(U5*<+A3CLA8
M((V,NKA']+].6F^WT/1Y9,2J>H^4=[A,+C?KG)9:(YI[0ENZ6N)CZ2VT<C7&
M*IR89Z,F$U!J->?)=$R%"4W9(@(**K) Q"!W9;'PY8 D^$6DW/+&5'%X;MP<
M(3]:D9B>&#MOW2I-CR6;/>\A_:A._!L')9L[VZA#UI"=^#8AL5^$*TQ9T;LF
MHFC$UFREHM$6;4!'.U1AJB@K"LK+*(RE9<<<+;0&XX"\MHEU1><C+3&X=<R:
ML2G"WI)M:=))+-F9Q*6*BSY5JF4GIY4!=;2XS5EXL] <2HU'*AG&TO-]05$^
M29-I2H@J)@V?2316?'' )(X9,&),L9839\V(1C$5+ !US/8HG($.QEC@9N""
M'!I#!AAGA0YX=RG)FP')3,>2S9[W4+[4)_3_ %MTV^ X.2S9[WD/[4)WX-CO
ML&)KK]<KY1^NDX*%[&CY"=V[<.BG0\EFSO;J$.^XI"=^#=&#DLV>]U"^U"=E
M;8'SMNW8[[!AKK]<KY1^NC@H7L:/DIR;=N'13H>2S8[W$(?\T)_C^=M^_JP<
MEFSN;R$'4D)WX-COL&&NOUROE'ZZ."A>QH^2G=NW"FLJ@HK336(\U RBH)4N
M0:K@/&#,202$"Q<FE&C)@Q%Q96.9:3)E1S8@EPQ1B$ A!!%'8!BZ3^&IX'B
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MT:8[M1$Z\.S[P1$N4ZR*E55)"DI"E)UA7RETI(40[@$$R+T_7%8ZC?2558O
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ME 1 *U-,+6_I,4USR_N-\-N_%[<5S/:-M':U5JLL,C:+Y[Z#U%6ET2Z\7%(
M'Y7MMF[G_=K>)=,G-+D_I:D(-KG6_P""I@7MG]2# .C8A#]-"US_ #LF>[+'
M%-D.&]X2?Z]C4BV#^<O30!#;>X CCLW_ ,^ .&^X2;Z];3SS#\ABFN86#_>?
M+,?%X\.W%<SVA;1Y*M59X8#KB^?EV4>@KTNC"V+B?/%M[O\ =IAG+=O>ER8-
M&M"W.=:'_)4L?_1P>EK0;YN=:ZNQ4L/:E!BFUW;WA)OKV-0-X_D+TT$.K\R
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M#^I38VR^=IPV_P#X_<V>).Q#07^1#0#?:):< "&[/4V]&?FP]\1"'/+/X#L
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M.NS$I?/'D+;N<9YT9!V(:S#L4UE_6\T?'ZG*VP;Y\_2@%3.\L:#9^IIX[?\
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M4P\NX!>WFWWVCENW"/@QV!3\KC_M@_\ 4@QOJUZ5&*/L$!TJQK#Y#X!^=Q]
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M"M:)<WL4KR;#54D6@:U4K&LXPS:":R:L$"N5B%PVN*G'URC6"-5(4Q6E]O\
M<0-*:X#Z(-#?MP]/%]"7W0P=Q!TI_K@4/^W+SZ>=I#\/!;50?%&FD<(7]+U1
M#??UPU #9S?'QO?/FMLSSLG_ +1KI'!MT>*( &Z[B?X\UPL$X?;Q\V+KZ RX
MXQ>,G-UUTDLWQ5]A;!IX4]*X3JVE%Q4+E'DB79.#9\=?H+XG"FUQX$'2FW5
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M)0:UU:Y91L^Y<_?W9GDY''G:6SIIBO<0-*8-E0*'=7;AZ7#P\D@Y@]JUL('
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M1@::'?KA=_GN_5#Y5<]*K/<0-*<;?D@T."U]JP\Q\.;2'P?<QR#@0=*:UO1
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M^W[OR8OV/U1\CCK9RZ98TJUAP'^E+]<"AP=2R] &VW/UHC?X;+87N(.E/?\
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MP#C](>$#X$>*^K2!@AS_ -"3(#_9>^6R_/CC&X=ADSTC73#?#D%BS^JEBQ.
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ML1E2CTR8U -QQ&0$1CBB,]BQ\<.8?'-:+6"UXL@ ._\ 1&H3^TZ;Y&A^!X"
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M:TN"+6@'6@@BO"':X,&%,:&#!@PHH8,&#"BA@P8,**&#!@PHIKBL7YTE4?\
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M.E=WDT.\G'B&[^_3P9VP=VZTKN\BAH?8Z\??J(_#GQ#5":*6'Y++;=YJ1?\
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MD@Z(8\WKKHSYODS"^B7H%[8:@:(W6#IHT'^N#CSFX"Q6PV+%A&^?R/)R$+V
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ME)<(. P8.<7+[7+Y>(L'Y!L%#G;YX>25-:)]':7I3?DM1,8323FR67V^Z2R
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M.BG29!=OH,F3*@@14P"O>I.B5HV(3?=#51J(TR36Z]2[D)NI'*M),@)+I%W
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MB5"*F5A 9DV9 $, #$( %Q"XB ;1"^[ZYT@<;G>S;J$W9*"XDY-08$)\,%Q
M>D1.$F@/!$?[)7FLKD"YV-,<S2<*6I10$9Q.*4X2*S&4@4$DV3*SI^/3*Z.!
MU3"+?.(J*5+*2LC2IL\M,/Q3Y<,"L3G ,L)L8P#$,4H ]4%@ 1WV$'G:H;P
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M0TIR)[O0T=7,.Q#<[D;99(<283.P3:=+K,,*!67VH4YAI+"67EO>!4("8[$
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M!&>A1]K9Q3+HY0]"<5U570%4Y.[9SXG(;3)1A6&.:4DQ8>?>1*$;QPP#"%Q
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M>45RK5VS:W6K/K]3K%3KU2CQ*K6ZI6D+@UBK5B O@HT"-"6E*X<2'$2I"TJ
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M;2+YPU%KHW:MUC4@AK\ZJB-=0J;/I'0!O4\E0Z/;ZI@C4KGK]/5-8J1,9<1
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,!@P844,&#!A13__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g201273.jpg
<DESCRIPTION>G201273.JPG
<TEXT>
begin 644 g201273.jpg
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M^9?*WW?V/7MX" ^0@/Q> \_$/,/HUXAN9_DZ9Z^9?*WW?V/196FCC?XLB_\
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M$R3!H6?'ESJE\K3HYTVMBI=BAK7!.#I\NLJ,Q /9&.4$H"'4!7(B7F', UW
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M4K7::!8F-PH5FL=%MT6J5>-M=*GI:I6=@L0P&(JTL%=>1LNW,4P (=V\*41
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MP7)FWOV$I;K+)L%^ZP'DI5+OV,A*N6BW=JD(JGWJ)^[5(10G2H0I@V=W,"E
M1]@!\HCY 'M$1\ #6O8X'_#'X@>WOB?;:<NYMVD9@QEC*IDRX%EN]I85M""A
M?=O"]^@(GTY5A99!T7W0F9)A&M^Z:*\W3M$I^A,3*%DH[2OQ;K-AAE_<^MN-
ML=U[(5VJ[69W(WJOO5F,_2\?V1MWD#BN#DFPINHFPY'BCJ2]LDF:R,A%4%9A
M',U4%[D+MD5C3PTD_/\ L/\ RO8N)SVF3#>V:<M&$]F<!7]QN98)5W#3^2I*
M25-@&@S[1R9J^C$7<&Z0F,LS\4=%=&08562AJFP?<F;JZN7[5_$HTM]SG$=W
MQ[Q'<J?<)N:RI=H"5=*NE,>L;$YIV*V8'4.9-HQQI3C0E2,S:D/W#?W5CY9\
M*)2>EOWBX&7/A*4I2%*0A2D(0I2)D(4I")ID "D33(4 *0A"@!2$* %(4 *4
M   #7ZV3%[)O6<;&LGLE)2+I%E'QL:S=2,C(/7 B5NRCX]DDX>OWJY@$$&;-
M!=RL(""21Q 0T4"XGU_1?B121;!R;((-0'S!L@DW ?E!$A 'Z=?ZB<X^9C#\
MIA'[1U-MMO[//Q2-QT;'6(N$8C!53E6Z+IC/;B[:ACU^X07[HR9RT&*C[9DA
MH8Z*OI!4YRIP9C)%$.8*B5,9)8+LB>Z=PBR-9MWFWV&<J%.,BWA,>9.LB30W
M0H*9&CU[(5?W0 3@B5115E' 0IU3$(H*9"JD#2?/C]_OXJI&!C!X@80'V@(Z
MX4 %BBFL!5TS!R,FL4JR9@]ADU ,0P?D,40_)JUO9>R0[UV+=RM5-S&UZRJ)
M,RJMVLO&Y9IRKM[S'O&??)UVW-VJ(!TBB^5,KWAA$JC1 H=X,-6\CA);^]B4
M6YM>?L$2B.-6O=BYS!CJ3:9)Q7'@LN1J@-@LL 0KVF=^Y4200/>(2M-G"RB:
M+1RY4.!1(6D>9'[_ )_+\UCOMEWF;I]F]I1MVV3.F0<0R)%45'D579@SFDSJ
M:!CG3:6C'<TG*42RLP,HH8$9FNNSI&.*C99NMTJEO!\'_M&-;W<6RJ;9-Y$3
M6<6[@K*X8P&-\E5DCN/Q?F>Q.#*)-JR[AWBCY3&N0Y($TO<J/7EY"IW&15/'
MP#V$F5HVLO-?$("'@(<A]@Z^TU545"*HJK(+)*)JHKMEE6SE!9(Y545VSE Z
M:[9R@J0BS9R@HFNV733704363(<I XCZ?);KT!YAS#X_H'Z0'Q ?: ^(?'IJ
M$S@);_YW?OL6@)7)4P,SG7!,\?"^6Y5PJ4TA;'$/$Q\I2,B/4R@(E>7.FOX\
M\XN8W)W<(BT.$4TD#II$F(O5WJF-*5;<B7N<8UBE42M3EPMMCDSG3CH&M5N-
M<S$Y+OCIE.H#6.C6;ETL"9#J&*D)$RF4,0HE<#R.?FO%MUN[G &RG#\_G#<9
MD&*H-&@R^CMA<B9Y/VF=6244CJE2:VUZY:V6V8,F9..A(ENLL)04>/5&,6V>
M/VU"K?OVFC>5N0D9>H;63+[0L/&640:2D YCYO/ME9%$I2N9N^J(.8:BE="F
M#@L/CV.)*1X*F;*WN5*!C#&WQ5^)-D+B8[FY?+$T,A 8AI_NC5MOF-'"PBA2
MZ$=R J3DFW*!45+_ )!,W;3UTD! ZK4!C*DU6/$UQJ=Q&9HJW/)]/(?==ENU
MTN.2[*^N>2+=:<B7"35,M(VR^V*9N=F>JG$3'.XGK,]E)53J,(CT"[[LHCR(
M0H  !UP5#B'(3G$.0!R$P\N0>0<N?D'Q:R3VR;.MT&\JWN:/MBPE><PSL:+3
MW>6K4>@A6JHD^/T-'%RNDVZBJ?4T''B=N$[-LG3M(BBC!J[ A@">3'/90^(?
M:XE&3O.4-KV*72QD^N >VJ^WV7:D%0"K"Y7JE';P(+)I<U$DFDR]364#N3.4
M"_AM%$ GT"K#]1@\C#]8Z&,8Y1*<1.4?,I_7*/RE-S*/TAJVS,=D4W6(1Z:L
M!NYV\RLJ(G[UC+T#*-?8 4%3@F*4JT=V-<QC( 10Y%(@@%6,9(JADR NI@7N
M&[-WQ2,"0K^RQ&-:'N%@HMJ+R0';]>C6.SH($2!146]"N<'1;7-*)CUD*UK#
M*?D7!BAZ.P4$Y2Z)VN^14,N)LT9AP+8$K7@[*N1L.61%0JI9K%UUL=#>J'(8
MI@]+][4C'(2)!$A>I&20>-U *!%4E"<RC:KX<_:E<IT)]5\6<0F!+E.A&50B
ME-QU)B4F&4ZRU-^"0E,@T"%:(P&1XYD (DDI6FLZU<",2+/@@;E*@9)U4?GZ
M_/56;EJU:8*:K%D@7RL7/5VR1$E 6"#DT.7?QLU!S#5E*Q,@B!BBJRD&;9R0
MIBF,D!3E,/\ (\O+1 2/0_E\%NC<=Y$HV6Z-5<EXTM<'>*#>(./LM2MU:D$)
M6"L$%*H%<L).,?MC&2<-G"1P\0$JB2A5&[A-%PBLBGW/6O1[-+Q.[%M_W"0V
MQG*-@=O<#[BI]9EBM.0<*K-\7YYDP%>.:Q(G[T6-6RX9!6#E8E I&:&0#U^<
M;)H.)ZRN7FPM >8 /M]O@/TA\0^T/BT5P/(Y7.FFFBRFN!'D CRY^P ^,?B#
MV>(_&/@'Q^&N=0K\?/>F]V7\.K*,G4I+W.RIG5PCM\QDZ1< D_B)#($9*^_&
MV,@(8KE-U4L=Q]IE(UXW,06E@-!',H7K*!BP3P"?DJ;O'^XG\GOPW22.)<=S
MP+;7-M-DG*Q0$HY<31N2,BL^^@[OEUZ)0 KU K@DA3\?"8RJ+.JM9";9B56Y
MO0+ 3KY*0B9")IE B:9"))$ >8$33*!$R (^(@0A2E#GX\@U[)M\P3D?<[FW
M&&W[$<0$WD;+5OBZ;5VBH*@P;.I YU'LY-KHD4.RKE9B6\A8[)(=/2R@XI^X
MY]9"%,5)))Y^)62'#WX=NX+B0YM0Q!@^+;Q\3#I,Y;*&5;$V>C1,559TL=)*
M4GUV907DYZ7%%RVI]+CE4YBTOD%Q*M%P4?-6")V-'#TX,NR[AX0T1*4*BM<D
MYS29$2G]PV38Z-F\AO7:@)F=DJ:)TEH7&<"=4IBMH6EMF3DS3NDYR;L#PAY!
M7)78/L=P]P^]MU(V]XBCD3I0S1.3O5V<,T&]BR?D-^V1"S7VS+I=2BKV5=)]
MQ$L%%UF];KC:)K,8*<=%H$'-'16M:!Y_'[+X[LG@/2 B'@!C>L;^D;F;ZQU]
M"4H^ @ AY<A !\/9KG6&>]K?OMFX?N*'&6=Q]];UUDX,Z9T^FQ)$9C(N29YN
MB*WO=Q_4"NFSR=D YI^G/EE6%=@$%"O[+.0T>!G0%)9!9<K^)+%CNUQN<HC'
M\UBDL,\>79CE)E7'^/TX!B@HN_>6="VIJUQ")9-RJ+NWDH";5HD4RJBR0%Z@
MI8[1-^7#4VP<7U?#NQ5O<HW9CO ;EP=G%*9DQ';]^[:\E3H8@O6!X29.6TP]
M&":DYC'<[(SSQ*L.F-X9R-%C&-6@6;E[#/Q1^--N8XEDX_J4@NXQ!M@82GI5
M7P%7)0RZ,V#1;KCI_,5A;$:FR%8R"1-TVAC(H46LN0(,+#/)) UD>PZ(KN6Z
MZ3EH[<,7J"R3EI(-5#).V+U!0J[1^V5*('3=,G*:3MLJ40,FX134*(&* ZA)
M''+&^*5C)8I6.CDCD:U\<D;VEKV/8X%KV/:2US7 M<TD$$%1$KF/8^-SF/C<
MU[)&DM>Q[2'-<QPX<UP(!#@00?,>BV?^5J*[QI>IVI+BJ=JR< XAW:O+J?0C
MSJ6C'(F+X'5*CU-'0D]4'K1R4>0AKS85/9XC^7Z?[<Q'ES#RUVG!6>D]^7#C
MVN[Q@.W<WU&I-:;F5-LJFJJVNU=?GI=[]*(D &;%"\Q!IYBW4(!THBT(K=1D
MU2F-THQQ\AY  ?%\?U?%\H^0_%KR+ZR=/V]/>H.:P=:,QXF=[<M@R02/])R#
MG/A@:7<EPH3LLXXN<29/<S(>"]>EW2C:O^M]*Q>7F>'Y& .QN7XX+O\ 4:38
MVR3%H ##<@?7O=H'#/>>P>35D!M[RTKBR]M5GK@25:Q&;Q%F2,<P(MD3*B5C
M-]!>9>]AUU3'6-TB8\:L^2 >KNQ+45[477-P4;Q&VMDRH_/*8?M.(JH.V-PQ
M241K\92X=)%#(M=*3TIXF-O;9(=/YRT.S*)K2D/8*4Z3;H1Z#)LULQF5+XAR
MZN8" \^0@("'ER\@ 0\!Y<^8>?CKHO%(VOCQ$>%3>&D/&DF=P6T15QE/&ZI4
M^^FI=K3HA=>R5AL=,GI2IK[B_P!V(9JS*"P2%NK\ L<@JM4CI]D?9*Z@2MER
M'3C)6"^$QSYG7/$<28GL<TY;'1<_]DK7C)0Q-\F/CR4I),H TC[3&B,;!2WO
M'P=K_$AQ6=#&_P#N-+>W&7I.!P',+30E>?-P?0C  8>=<CJ<[@H<'BQ\3/)\
MM<\C+3M/VE8FEV3+(UHB3*QLYD:TJH$D4,34*7,02Q[P(Y5K)WJU-2.%ZE!O
MXQI'$)8[!&.HR%BB4^P9+NE*Q_267NQ:LAVJK4NH1X H)9.PW.:CZ_76Y@2*
M=8$',E*,@7,F0ZB3<RBA2&$G(=NYL/VB4G8MM1PYMBHQTWS3&]9(WL=D!LDV
M=72^S#A::OMU>E(DFIWUEM3Z2?MT5C*G81@QT6104&"(%[S+IXQO)Y/H/ZG]
M^J]KPWA+$NWO'=<Q-A/'E3QACFILTV4#4*;#MH>'8D(FF11T=% O>OY1Z9,'
M$I-22SR9EWAE7TH_>/%55S^I:::*U-<"4#>8>7D/D(?((<A#Z!#7.FB*M+QF
M. 3B[>36;7N VI5>M8OW?QZ3B<D8B,(TK5#W#@@FHN\@[>S;IHQ$#DM_XC7<
MEIH-S24D*<1?COXUVA-U_773T#-U:<FJQ9H>4KMDK<O)0%AKTXQ<1<W SL,]
M7C9B%F8QV1-U'2L5(M7+"09."%6:NVZJ)PZB#K=5B " @/B AR$/: ZH$]J:
MV 0^&\WT;?)CF-2CJKN0E%:1F&+9M>Z:,<VU^!5DH>Y%,BD1LD;)-+BG3>73
M$ 46L=+7E3F6=V!XH!5O:/4?G_-5-==NQ]^,#'_S@4+]<8/74==NQ]^,#'_S
M@4+]<8/15K=(%\A_./\ IFU"9VBKX'O=Q_-86^__ !?J;,OD/YQ_TS:A,[15
M\#WNX_FL+??_ (OT5[O0_0_9:O4WF/RC]NI<. [\+ILA^<.[?<GE+41YO,?E
M'[=2X<!WX739#\X=V^Y/*6BI;ZCZC[K:ED*4R1 ,4#!T$\#  A^]#XAT[E+_
M (I/^@7]FN4_X-/\POZ(:^]%>M8WVDX #B\Y^    #'FWGD > !_O30P> ?(
M !\@!J"/4[O:3_A>L_?-YMY^Z:'U!%HJ7_B/Y?8+9)=EV(0W"LK'40IO]_S<
M%^^* ^=Q; /F ^8 'U![-6*NY2_XI/\ H%_9JNOV73X*RL?/YN"_7)MJQ9HK
M6^@^@^RZG=K57\>TVV7RRJE8URE5J>MM@>E2*<S2#K<2\FI=P!>9>KNHYBY.
M "8H"( ',.>M.AN(SI;=SF=\O;AKT[4>6K-&0K/D63,H E*T1L4BHYA8=NCU
M'*V95ZO%B*^P:IF[MJQBVS=/U4P$=J_Q3VV1Y#AS[TH7$=4M]XR-9=NF3*C4
MZI08E].W"<D[?!+5CT*!AXQH_D9)Z+66=*^ALFJKE=!)8B/=GZ52:Q$>&OQ#
MRB)";$-X'03U"<MNF5>0$+ZI0#_R8\@*  'Y-%!_/D//]^7[^O\ -83G.1)-
M1501*FDFHJH( )A!-(@G.(%#Q,(%*(@4/$P\@#Q$-;)_@/\ !_QOLKP70]Q>
M5JG$6+>#ENI-+1)V&69^G.,+5&X,&TC$XRI(/ ,G"S"<(NS-D2RL&S28FIQR
M^@BO/>Y$L6ZU+[:+PM][%MW6[9JSD[95N=KN-9K/^'VF0YZXX%R+#U.)HI+]
M N[>]LLI+0D?&,8-.O-9$DDN^>MFP-5%"'4$3E3/M84R%3(!"@!2EY@4H !2
ME* ^H4I0Y 4I2\BE*  !2@    '+1&#XG\OZ'E?0%*7R  Y^?(/,?:/M'\H^
M.N=--%8FOYDS"Q%BBI*"GHN.FH698.HN7B)9DVDHN5C'R)VSV.DH]XDNSD(]
MXW440=LG:*S5R@H=)=)1,QBC_3TT1:R+M /#4JW#XW90\YAZ./$[>=R<98[W
MCRN$3$&..;9!2C)#(>-(I4"@3WLQBT[!V*EMC""L7 3IZV4%&M;0<KP.:O9]
MKY+#?N&;*CKJ)!80S=DX(M(2-Q7/!FQ@B,^H10RY796R<B2M%7*BV6;'75:>
ME+-U2LR.:)FBI<.''C]^2M^]D-R))L,_[R<3%<+>X]GP]B_) M?6%N65I-YG
M*HHY'UNDBZL?>T$ 'H$RR;< ZR W #SF]I9S',8FX4^5HB$65:NLVW[%N$'3
MM W0HG 6BPJ62V-C&YE$$9:L4V5A' $YF.WDU4Q "',(5Z>R/?RW]S/^:BT^
M^2G:FC[5Q77$OPU*9,H$<'3J&Z[$LL][EOWR*328JF3*D59XJ'BT0*^GF22:
MP\RJO%VS00 7!3 4@3V'\Q^1XY^Y6NI$1,(F'S,(B/RB/,=9 [3\!RVZ?<U@
M3;?"RA()_FW*M0QW[O*)>D%@(Z;D"FGY[T?I-Z0I"5UM+RK=N)3%7<M$43@*
M9SZQ]UE[L"W%QVTC>KMCW(S;9X[K>),NUVPV]M') O(*TE^D^J]V%@WZ3"X?
M-JI8)=ZS;$ 573IJDV2_"K$T58]1S\UMB-M.V?"NTC#=.P3@.D1E%QO3&";:
M-C&1 4>R;TY2#(66RRJA?3K';)YP3W0GK%*JN)*2?*'.JL"1444O>]=*QSD2
MBY9HM3R3C.UP=XH-V@8ZR5"W5N0;RD'88"40*XCY6,?-CG27;.43 /@(*(*@
MHV<$2<HJI$[KHOT)K@0 P<C  A[!#GY>0_*'Q#\6N=-$4&7&CX/N,N(CABRW
MVAUB!K6\B@5]:1QGD9HS(RD,@-8%HY=$P_D)VW HSE=L9"BQK4K)$=25'GU&
M+Z(<HPSB>B936(KH.&JRS9VV<,G;999L[9/$C(/&3MLJ=!TR>(& #(.V;A-5
MLZ1,'4BX242-ZQ!UNNC (@/+ES\PY^74 \PY_'RY@'EX^SQU1]W==EKW.YKW
M3;B,R8HSQMNJ6.<LYCON2ZC5K,RR@2>KL;>IQS9G$/)%A*P]B0592\G))I"P
M=+("T]'-U H*A"E6]I)! ^O]E35A9V:J\S$6>M/EXRR5F5C+)7))JHHBYCK#
M7W[>9@G[=9(Q%4EF<LQ9N4CIG*<IT@$I@'D.MQEM8S,UW%;:L!YY9^BD2S'A
MW'&2U$&1A.V9O+G4HJ=D6"1A #"$?)/'C(>8 (&;B40 0$-4<"=D?WOE.4W^
MZ9VI>J8IO_1,R>8" \O\3_Z_ZM7*^&[MHOVSK9!MVVR90L]8N5XPU2%Z=,66
MF)RB58DD&UDGGT(,22:8QLJ"+2!?QC!87S))P9TU7,8ZX&*X5++ 03R/(K-_
M3331335 WM:N?5;9NIVY[<HZ647AL/X=E<ES\6D< ;-[GE^QKQ46HZ3#Q.^9
MTV@IF0,H(]RSL*@) 4'2HFOXF'I*8WL*(_4'/6KH[0S<7%QXO&Z\5>^!"HCB
M&A,$EN7)%G7\,T9ZH5$ 67 $%I*=DG9.7="8SE0YT$U#&$Y0>?+ZG_E0KZN3
M]DJVCL9^[;B-[-GB0<>\1NQV_8F>.6Y%$&T_9&+*X98F6*APZD9%G734:MHN
M41 2,Y^P-#<RN5 U39 !,(%#S$0 /E$>6MG)V;C&[.@\)+;Y+()$3>Y4L68<
MIRQR='-PYG<HV6"C553$.<#*$KE6A&Q0/T*))()H*)D,F("4&#D_0<J=O7 B
M!0YB/(/^\1Y  !YB(B(  !XB(@ >(ZZ5D?)-!Q!1[/DO*-QKE Q_2XEQ.VNX
MVV69P5=K\2U .^?2DJ_51:M4>H2(I <_>N7*B35JFLY621/1*XM/:4KWFXUH
MV_\ #\D[!B_#ZPN(:R[C#)/J[E;)#/DHW>-L8LUBH2>*Z<^ 3 2TNBMLF330
MQ3L$:(B<WIY6D@#[#YJ<CBT=H"P7L.2LF%<$C Y[W;-BK1KVMMWBCC&F&GQT
MO5=Y:GXI=-1[86ACD51Q;7'A;(L8H!:)*F,EFSIYKV-R&YG.N[C+$_FW<3D>
M=R;D>PB*2TQ,'308PT258Z[2L5& 9E2AJ?48TZA_<VM0#1G'(&,=TX([DEW;
M]SX8HH=51154YU55E55UE53G5567<*'6<+K*J&.JLX<+**+N%U3G67744664
M.JH<YOZ,)!S5FF8BMUN'EK%8K#)LH2OU^!C7LS.STU)+%;1T/"0\8@ZDI:5?
MN#E091T>U</'2I@(@B<W,-%27$_3X!?RP 1'D "(CY 'B(_1J:KA8\$7<IQ)
MI6.O3DC["6UAJ]($SG*PPQUG=S2;N 3?0F$ZZ]! EVE $BS9S;W1D\?UUP10
MKE_/RK92LJS<<);LS)"C7=P'$HA$7!A(SF:?M+0D"+LT3&!-RS?Y^F(M<R,B
MX( E4-B: ?'B4C@#>]3<N4SZIH72X6$AZY$QD!7XJ.@X.%CV<3#PT0Q:QL5$
MQ<>@1K'QD9',DD&4?',6J:;9FQ9H(M6J"9$4$DTR@4"DUGQ/Z?Y_?*Q,VU;%
M-O&T/;0;:Q@6HJUG'"[::7E59.3>3UCM%KL+!JSF[U:YMZ8%96TRRS!@[>.D
M$&$>V]":,HB,C(QFS8H18RK)Y#24C#R1#)2$2_>1CY$P=(D>1[A1HY#D/Q=\
MB<2^8](E$.8"&K"@^("'MU#;N_J/O4S/+/D4>[8W)@RM#<0Z0)Z8H4T;,$YE
M\S^GL?2U $ ,'IQ1'GU 8>GWM=:JVYKVO;=!$#/AK\F)O/:/,T,HT2UY)7?_
M )UKU40QCX29)Y'XB5VN]EK837V'-ZK,_B'+469.FQSO(7L8\,FCB:2!WSTK
M#Y9#\64&\\]H6-!EA']Z'+^W]O9K*G9W=RU[+!:V]5(:+OT6X@UT5A$4#RK$
MBLE$=8#U$,*Y22$;TF(8JGIX$, \PUB*97\O,/J /[?V'7[(:>?5V9B;!&J&
M3D(*383#$Y1$O)U&.DGB(<P$!$#G1 A@Y\C%.(#X"(:Z7:/L4VG[;KVRPN>3
MB,I5M3-9Y&:GWB*_7'S]YHR6*Y/GY2'XKN+N&L1;7JF>UV1K2<KC+-:!SARV
M*Z&>)0G)X_\ KW8Z\X' \XPH.=F/#>C\,=I8E\&OH98V-,$3N2=W&-T4P(9L
M:B2D$G.X9(*XI))BC5+=D./@Q%!$0+*T8R!0(8AU$[^8!R  \?  #Q\1\/:/
MMUAI [;:99-XE:W]0SU L]/;1E-OKAAZ$D*C^NR^3*_EF EQ>D #%<1O=3$0
MJF<14.B^0(!@(U$FLS->QT,L=B**>%[9(9HV2Q2,(+9(Y&A['M(\BUS7!S2/
M(@@KR3?#)7DE@F8Z.6*5\<D;P0^-\;BQ[' ^8<QS2UP/F""$TTTU8HIIIIHB
M:B+XZFW^/W$<+;=C J0X2M@QQC]SG:DG+U>E1EIPRJ6[@\9@4#\U'5=86.%<
MI] ^D1\L\;=28J@H6737G&8:NUN^)\FTQ_'EEF-MQ[=JP]BCF*4DFTGZO+1+
MB/.)S$(!7J3PS8PG.4H KS,8H )@+!'((^8X6F&$2CZQ!YD-ZQ#?\(A@YD-]
M)1 ?IUV['WXP,?\ S@4+]<8/73$$5&R#=LJ42*M4$6JI#"!C)JMDRMU4S& 3
M 8R:B9B&,!C 82B8#& >8]SQ]^,#'_S@4+]<8/14+=(%\A_./^F;4)G:*O@>
M]W'\UA;[_P#%^ILR^0_G'_3-J$SM%7P/>[C^:PM]_P#B_17N]#]#]EJ]3>8_
M*/VZEPX#OPNFR'YP[M]R>4M1'F\Q^4?MU+AP'?A=-D/SAW;[D\I:*EOJ/J/N
MMJ8G_!I_F%_1#7WKX3_@T_S"_HAK[T5ZUCG:3_A>L_?-YMY^Z:'U!%J=WM)_
MPO6?OF\V\_=-#Z@BT5+_ ,1_+[!;)3LNGP5E8^?S<%^N3;5BS5=/LNGP5E8^
M?S<%^N3;5BS16M]!]!]DUQR#\OUC^W7.N!$ #F(@ !\8Z+*<@_+]8_MUSK ;
M=IQ/]BFR1%TAN(W%T.I6I!(ZB.-HAXO=LJO3@F11(C?&].1FK8@1<%4P3>2D
M=&1I0.!UGR20"H$ >=.UR[=X#TUCMTVM9?RBZ(!TFL[E.Q5?#U<.H !T.B1T
M2.1[<N@(\Q!!U&0S@Q>76*)A$I2P7 >I5O77R!R#S # 80\P*/4(?0',=:X;
M,?:EN)?D)RL3&S3 6 HO\,1LG5<=.L@V!-)0P=V9S/Y-FYF+<.4B!T]\WJ#!
M$YC"86P"4G3&MD3B^<3_ "DHY/;=]6XI-)V*@KL*9=$L8Q@E4 "G2(PQE&4]
M$B(D#H!/Q*!3'#Q[Q03E'O'R*VR$K-Q$$P<2DW)L(>-:)F5=2$L\;QC%ND0.
M9E%W;]5NV23*'B8ZBI2 'B(@&HH=UW''X:VTJ-D26C<=4<H7ALR7<,,88%>-
M<O7*1=(@8"1SI>J.G50JBZRH%3*XNUIKK5,!,J=04TS:U=%VR;DK);E1[DC(
M^0\BNUC"=9Q?[Y;KLJJ<3'.)E!M,S+ 8PF54,(B'[Y10?,YA'HQ"D3(":1")
M)%'F5)(A4DBC_P#*FF!2%^@H:+!?\A^:DVXIG$XRIQ0,]1^4+E H8^QW0XF0
MJ^&\4,I4\XE3:_*/T9"9E)R;%JP2G[M:W3..7L4JUCV4>V;Q<3!Q+<6,6#Q_
M&7KCF'48G,.HG1UE 0$Q.\ QD^\*'B3O"E,9/J .LI3&)S IA#G15D\^95K3
MLCW\M_<S_FHM/ODIVKCG$UVDJ;XMC&XG;5'*MFUJO=(,]QZ]=@B"#/)E,DV%
MUQZ==9PLW3:LW5K@(R+D71E2 A&R#Q0>92B4:<?9'OY;^YG_ #46GWR4[6P,
M$ $! 0Y@/@(#Y"'L'16L_"?J?L%I6+%7;!4;!.U2V0<G6+55YF4KEGK4TU58
MS%<L<&^7C)R!EF2Y2+-9*(DVKE@]04*!B+H'Y<R"4QOXWEY:V+'&KX!<!OE=
M2VY?:P:L8]W7),0-<*Y*F+"47<(BQ0319>^"40242JF3F3-$K")O2S1Q'6%H
MFS@KL"*#:.LT'K^\SX/S!MTR),8FSMC6X8GR1!*G3D*?>(9>&E3)%,($D(HZ
MG>1]BA')0!5C8*X]EX%^B8BS*273-U:*LM(^GS6>G#RXOV\CAMNW,1AJTQ5S
MQ!+R)Y6?P/E DG-8Y<2;CJ!Y-591@^93N.[$] W5(2=5>)1TPL1%S8Z_.N$$
M%4[?VUKM46Q'+#=C%;C:QDK:K:SI) ]D96(=97Q<=QTID4]"N&/X]Q:6:)E1
M.H4]DQ_#HI(!^%>F.'CKN= $0\0'D/M#19#B/C^16X;P9O=VA;F&;-W@/<KA
M/*YWI>:<93,CU>3L"(](G[M[6!D4++'K=(&$R#Z(;KE INI,.D>64?67XQZ>
M8\@ZP$@B/L #  C]'/6E   *X2=E*4KQ$P&1>% "/$#%'F!D'9.ERB8/B,DJ
M0P?$(:SGP;Q-.()MN.Q)AO>%GNKQ<<<IVM8E+Y(7^EEZ1*/=FI>20N%9[H0*
M!3)HQB/J>H4Q T4O$^8_JMNUIK7Q;>.U@[T: ,?&[B,,X:W"0R!R@]G*T:7P
MC?G2?0!#*'6C"7&B.G(F#O1*G3X1 YA.0!1()1)82VA]I0X<VY9Q'UO(EJG]
MI]^?*(-DX?/2,>PI#YZN8"]U%9=KSF3HJ213#TIFM[FFNEO5$K3J,)0*0<T_
M'CZ^2L%Z:_%&R4?,,&4I%/FDE&R31N_CI!@Y0>,7[%VD1=H]9.VRBK9VS=(*
M)K-W3=55!=(Y5$E#D, C^W1233331%\G#F0X!YB4P?6 ZU87'SBWL3Q>-Z:3
MY,J2CVX8YEVX$5(J!V$I@[%Z[)4PIB($.HD F,B8042'P.!1$ UM/]:X[M3N
M'GM!XE,3DP41&)SUM^Q[8$'8 ?NU)_'#Z<QS8&HF,'1W[6*8TU=0B8\@1?MS
MB &.81*#QY?0_O\ LJV)1Z3%-[# /U#SU?\ N'+Q8-JNP'@=;2K9F^U \O32
M&S+4,?X5J()O,G9*E*?FK(# /<6(>K(-XV!1])9>^"]3CEA4(8ZBB8/',B9I
M#NZ &OHQSG @'.<_=I@BGUG,?NT0557!%/J$>[1!===<$4^E+OUUUNCO5E3G
M*L'CGCY<*3OB1\63=)Q+KN9[E2;]Y.&824].QYMYITH^-C^K&0$Y64W8EUB,
MW.1;\1(YN]N-A9I)QYU5T:C!59BLNV7C"\_/7 B  )A$"E*4QC&,(%*4I0$Q
MC&,(@4I2E 3&,80*4H"(B  (ZL'<)W@#9[W^+5W,>:/?#@#:2Y.B_:VQPP1;
M9-S%'E-U"WQ+ 3+=5.*KCPI13-E.SQRT&=(X'IT-;S]Z[CB>;C\R?W^BBNV8
M;%]RV_K+"&(MM= <6N6;^B.K?;))92&QWC2$='Z2V#(5O.W<-(-H<A55(V);
MHR%ILAT3M:U RRY5 2V+O"RX)6VKALPK*Z"DAF7=#)10M;1G6S1+=$\$5XB4
MLE7<0UY8SPF/:NKZS=T]3=/;G94N8V*PJL3-H2/DDVR[6,"[/<3P&%=NV-X#
M&N/Z^03DCH= RDA-2BI"E>V2USSLR\W;;5)B4#R=CL#Y_*NQ B0N"-4D&R.0
M>BL:T#U\S]OI_E         #D !X  !Y  ?$ ::::*::P.WXU )&B5J[-TBF
M<56=&,?*%( G+$V1,B &4. <^A&7:1Q2%$1Y&=G, >L(ZSM64(DDHHHH5(A"
M&,=4X@4B92@(F4.8P@4I$R@)SF,(%*4HF$0 !'4"/#:W[1?$XC.)KBX;"-@3
MQKN3NK/#2[E5LD1; MFCR1N'95@V*4BYVA;ECNV20KF.MT)R[ IU" JD4>#]
M2=9&WZ)M&O",23W\38]Q:1S_ .I5>V[C3\P!?KUR[C_MY'HN9].]C_Z2W?6,
M^YY9!0RU;WT@^9QU@FIDFCX<NHSV .?+N(*\E.J <QY_2/E[?V^'AK_ R_Q@
M//XPY^ >'B'AYB'R>.OSK"LDH=)P0R*Z1U$ETCAR.DND<R:Z)BB "!DE2G3,
M7ES*8@@.OR'6 /,>8_;X_+S^+XS>7Q:\?R""0000>""."TCR((/!!'Q!\_7R
M7KQ%"'!I;PX$ @M((((!!#AY$$>8[?4>84U&R:[%M.%F4,LL"C^C2K^MJD$3
M"J$<<P2L*<W5S_!@Q?"S3$/  8F( >IK+[4/&PO( P>4I:E.%NAC>8)0[5(R
MA2$-/5H5'S7I P@ J.(EQ+I=)0ZCB@D'B!>0S#Z]4N@6T#:>EVNS22>)<PT3
MM=O GES9<0&0U>\\DN?+C'4+#W'U=,[Y+RXZ]ZL=4ZH;%79'X=/+RLV*AP.&
MNAR_=-9#!P.UD.3;?KL ]&PCZ!IIIK<RTVFFFFB)KKMODR0M5LDNJD==.+@)
MJ1413,4JBI&$6[=G2(8_J%.H5$2%,;U0,8!-X .NQ:P+XHN94=O_  []Y>5S
MNB,W=<V]9)903@RQT!+;+= .:33TD5$_7!TYL]CB4&9"<CJ.3I)E$HFZ@(M1
MLHX*\44>%*)"O%%7I2&$!,0KQ4[HI#"'@)B%5 IA#P$P"(>'+7:\??C Q_\
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M#J\"W63:-Q.1!9])2\S*+@+2#K=?BFKR:L<Z\_P6)B&3IT8BZP(-7&R!X:_
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M@6".01\UI>1 0$0$.0@(@(#Y@(> @/R:^#& A3G-SZ2$,<W2 F-TD*)AZ2E
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M_" ? 0'RY#S =>577S2WZ3U&S$<4)CQ.=E?GL2YK>V$0WY'26ZK'#EK32O\
MO$#80>YE;W60AHF:#ZR>SWN,6\].,/++*),M@&1Z_EV%W,AEH11LI6Y.?XW^
M_8_W>9TI';):][8TN="_CN50N$C2+96[C%&'W0K$W'3;9,! ._%@X(HNT/S
M2]V^:]^R5*(" IN#@(" B V1:S88RV5V$L\,N5S$V"*83$<L0Q3 =G(-DW2'
M5TB(%4(10$U2<^9%"'(8 ,40"L 981_)_5R_M\7,?/4N/#XS0E,UZ3PU-.P&
M5JX.)NI"L<H"[K+QR4TC&(]1@,=2"E'(KIIE PA&R:0% $V9^G8_LH[Y%AMG
MR&F7YA'3VAC;&,[R!&S-T(S_ +()(#79&B9&]Q),DU*I"SETC0M=^UMT\FS&
MJX[=\?7,EO59'ULJ(VDO=@K\C V=W +G-QU_PW=H $<-ZW._AD3BI*M--->A
MR\Y4TTTT1-4_NUC;QX>M84PYL@K$XDI<LIVV.S+E"+9N#"XB\7T!5\A2F4PF
M0X$32N.1SIRD8@J43N4<>R"X 5),@J6.]\F^+!.P+ MISOG.R-F#"+:NVM.I
MK1XT)<<H7/T8ZL11*+&+J%5DIR47[LKET!!C:Y&"ZL5@<L(:/=.B:IK>!NHR
M=O5W'Y3W,9<<HFN&39\7Y8=BNY7A*=68]$L=4:)7!=&,N6 J$"@TBF1U>E:0
M<$?33LH/Y5X(E!YX''Q/V_?]UC5KMV/OQ@8_^<"A?KC!ZZCKMV/OQ@8_^<"A
M?KC!Z*I;I OD/YQ_TS:A,[15\#WNX_FL+??_ (OU-F7R'\X_Z9M0F=HJ^![W
M<?S6%OO_ ,7Z*]WH?H?LM7J;S'Y1^W4N' =^%TV0_.'=ON3REJ(\WF/RC]NI
M<. [\+ILA^<.[?<GE+14M]1]1]UM3$_X-/\ ,+^B&OO7PG_!I_F%_1#7WHKU
MK'.TG_"]9^^;S;S]TT/J"+4[O:3_ (7K/_S>;>@^0?W)H8>0^P>0@/(?B$!\
MA#4$6BI?^(_E]@MDIV73X*RL?/YN"_7)MJQ9JM_V66:C)/A<M8YDZ37>UK<9
MG6+FFY1Y*,7TA*0%E9HJE'Q_PB%FXUZF8.93)N  !$Q#@6R!HK6^@^@^RUWW
M:P;R_G^(9B:DJE42B\?;5JDX8)BNH=%5]?,C9&DI=X1 3BD@JHC7H9HJ=-,B
MBY&*7>J*$21*E6 U9A[5E7I.*XE-'FGB($C[/M.QBM$+E[P07+!9 RW&29!$
MR1"=XW=+(]1$U%>E-=$R@IF4*0:SVBI=^(_56]>R+X8KUDS]NWSO*-FCN>Q9
MC+&^.:J+A+O%XP,M6"T35HD68F()$5G;#&L/%'6*8JP-EG:!0[IPKU7R]:^3
MLH^Z&I8HW=9JVZV^6;PQ]S6.ZR\H"SQ=NW;2N0\.R%CD_>LD94I3*2T]3+?8
MI")1*N!G!JL\:HMUG3A#EL&@$! ! 0$! ! 0'F @/B @(> @(>0Z*UGX1^?/
MZKG333123334?O$4XC6 >'%@N:ROEV<8R-M?,)%MB7#T?+M&MYR_;T$0!K U
M]H8KERQA&KA5!:W71PQ5@ZA$BJ\?**OE(^-?D)X\RJJW:Z<_0D_E7:3MFB72
M;B7QU5;_ )HN9&[H%2L5<BN8JF49B\;IJB1%\>,J%NDR%72!P1B^:*I&(@]-
MWU.K7NFYG<1DK=EGS*FXS+LD23R!EJVO[1- V4<GC(=LH5-G!52OD=G4<-ZS
M4(!I&5FNM53"HE$Q;8Z_4[5<J*>%Z*AQY)*M:=D>_EO[F?\ -1:??)3M3(\;
M/C>[E^&-N5QGAW%&&\(WZGW["+')8SN1W5]).I3WOZMU5EHMNE59Z+8DC&K2
M'A7"!EVYW2KE\[YK&133(G#)V2-\T1WU[CF"JQ2.W^TQ19F@(&ZETHS,=",_
M.00*) ]&"09B<#&*8W?E[L#]*G1F_P!KMP ^D*5M$W01;%11E4;-?L&7)XFD
MH<K9"^L(Z\TA9=0A131;^ZE)M,>!EC%ZWDJT22$QU.G13'(82/7GZ_)85?WW
M#O?_ .;+M1_+_A>9/]</#^O5C'@;<6')G%)H>X.6RYC_ !KCRWX7O-*AVL;C
M5U:5HZ1JMVJ[V2CI.02M<A*.TWQ9N!L##K:NP;*-T$ ,W26(91?6-:FOX$'$
M8@.'CO-1E<IR[R+V]9V@&F+LOOTP6<,:<Z3EDY''^4G[!)0HK1]*F7$FQL;A
M!)P]94^T6"1;-W1XXK1<L-<>1R?+]A;1'37X8R3CIF/8RT2^9R<7)LVLC'2,
M>Z1>L)!@]0(Y9/F+QL=1L\9/&RB;AH[;J*-W*"A%D5#IG*8?W:*U----$35*
M_M;VUNFM*[MGWC0$$UC+L\N$EM\R-,,F?=GM$"[K$U>L<+S"Z12HJ/:J\KEN
MB8URY [Q:.L7H!51:Q;1%&Z@(@ "(CR /$1'R /:.J//:T]VU&LLMMWV8529
M2E[ACZ>E<Z99;,735=O55)FL/*ACBMRQ$N\7;V&5BYFS6D[!91NJQ@C0SURV
M43GHY4A1?^$_E]U3%U,AV?R?D:]Q>MG*L: F-,3N4:R_)U+@4T5-X/R25[W@
M(&*)RIF:MURD6$6W>HI'6(;NR<H;]6!NS*XLEL@<5G'=M9-G:L5A+$N9<CSK
ME H^CMO=>LIXLA$'BOD0CZ2R$<R*?,3+J,3 4HE25,0JF^H^H^ZV7!!$2E$?
M,2@(_*(!IKZ#P  ]FFBO33331%#)QH>%%5N)I@! E9&(K&YW$+::F<&WE_R:
ML9,SY%)>:Q5=7B::B@4B[+,6(EDA1<N:=8VT=9F"2K8LY'2VL2R7C2_X;O\
M;\5Y4J$[0<C4&=>5JY4VRLQ8S=>FV(E[YF\1ZCI*IJI'1>1TBS6<QDQ&.6<O
M$/'L8]:.UMT1J&SBK<&+;QQ,JHI8G8-L2[G*Y#A'T//,%$)O'+IHT!51C3LH
MP:*S$;]10555!HBH\:66J*+K.ZE-,$W$E&2I0<WGS'K]UJT@$0'F \A#Q 0\
MP'VZS\V4<3K>IP_I4JNW',4G$4M=\H_FL.W! USPU8'"YRG>+NZ+(ND$H.3>
MB4HN;!29"J6)<P<W,JX+S(/\O>[PXMW/#ZNCNL;C<6RD-6U)$[&K9?KB+VP8
M9O:8F,+5:M7U-DW8M7[E$"JGJUH1KUO9&,*3F#Z (X6P8$!*/(0$!]@@(#]0
MZ*OS!^(*NOX1[7HD6.CV&Y'9H_/+$Z0E;3@?)4>O'.A$P =9G1LEL8YW'@!.
M9P:C?Y7UP @.ND>L,@Y?M=>TU"/75@=J6YN3E2@7T5E*RN&X1@L(CZX+R;:[
MSBS8I0\0$D6Z$WB'24>7.@YIHL]SOG]E:1W7=JLWF9=CG];VSXSH&U:&>@=(
M;<Y>ES-E5) Q3)C[F2%A@H3'U>743-ZRX4FRND#^NR?-U2D7"L_D#(=\RO<[
M#D;)]TM.1+_;7QI*SW6ZSLC9;1/OC<P!>4FI5=R]< B412:-N\(SCVX%:1[9
MJT330)T[7Z&C1V_>,H]BU=/I"2=(L8V/8MEWLA)/G!P3;L8U@U36>2#YPH8I
M&[)D@NZ7.($11.<0+HL$D^I7Y]3?\%G@_P!TXEN7O??>FTM5=H.*YYC^ZI<R
MH.6JV2)AHLB[5PKCZ0#NB'FI%J*?O]L+910E#KCPH !K/+PS9+-3A<]FKSIN
M-?5?,>]YI8=O>"/26TJVQ(NFXB,]90CDCD53:2C-0I%L-564 IDG3V8(;([M
MB*I8F JZKAC9$K]6*,3XWP;CRI8FQ%2Z_CW'%%AFL!4J?5XY&,A82*:$Z4T&
MS9(.I198_6Y?OW2CB1E'ZSB1DW;Q^Y<.52DUO/!/I]_^%V:OUBNU2M0M.K4)
M%P54K<)'5N KL4Q;L86&K\0Q1BXJ$C8UN0C5G%1T:W08,V**94$&B1$"$ A>
M6H*]W6WYWA&[JRL(R5-CBW.G#NN.DR'.A!R"ACKO:F[4Y&[HS0!,XA#K&#TR
M*'N4S*+QKOIGQUU.\4>KY&K$K3KC$H3-?F4"HO62XG((BF<JR#ANND8B[1XT
M7(FX:.VZB:[9=,BB9P$! =3=8>EM'JEK#L:Y\5/.8YTEO7\G(PN96MN8&RU;
M)8UTGN%]K&16@QKW1N9!:9'*^LV)^X^C'5>_TGVIF4;'+=P.1;'3V+%1O =:
MIM>71VJP>YL0R%!SGRU#(6MD8^Q4?)#':?*RKPHX$?#GR^WZO'ES]@^&O[M+
MO,_CVV0-UJSWT&>KDBC(,%C=1D5!)U$<,GA"B7OH^1:J+,9!L _AFCA4@<C=
M)BY+;B=FV1<,NGTY76TA?,<]2SA*<C&2CB8KS4!,<$+7%M"'.F1NGR*,^R3/
M%N +WKI.+4,#?6% K@8.H#E,4?(Q3 8!^0P"(#Y_%Y#KRSS^ VOI_GVTLS2O
M8#-8VQ':J2GNC/B5I6R5[V.NQGPK$3)6L?#:JR/8'@#O$C7-'K;K6=U#J1KC
MKV#O8_8,%DZLE2Y!Y2<1VH71V,=DZ,H$U69\+W1S5+<3'EAY['1O:YTD.[C?
MKN;P_AR#WQ[9L;PFY'"%$CTHK=IM@<*KP65L;1S 7$@]RUBZY1$9(KO&T&W<
M"2]05EK]CAGE.0B+G7S5[W&N0.\<<,]J3X9>1&$:.2'6;,!S+DJ0/FEVQ;)W
M.#:J*"G^%;6G$KB\-'C 2*=ZFZ5CX]8R)#'.S3,)"'\TQ3F:\85M"=II,D5L
MJJF1K,Q#TAG,)98L#B8\5.1_44'+<P&4[AP04WC!50RS-PF)E4UHDM_O!WQE
MN@FI_/W#J2KF-LJ3[A[/9%V26V<B:K$SMA>N!7?S&V"UR(1=5(>6=K*.U\53
M;R#8$='<*UEQ7BJMZZY]$>C'M"Z_OM&GA=CN5<-ND,<<$L5A\=:EGI& -]ZQ
M<CBV)MJ8\/GQ;BR9DA>ZFR>NUQB\U>N?LU[-TYOW<]K%&YG=$FDDL1SUHY+=
M[7HW'N-3+Q,#IO=8.2R#*@.@?&UHNOKV7M;+8TF.T<\(*+C7;]MNC?SB[=,#
MIQ4+@_/#F4>F$P%!)HBZQTQ;'4\>8]\\;IE*!C&4 I1'47FZ?M:^&8**>P^S
M?;U>,D6=5$4VMWSL9OC:A1KGK'DY)3Z_*3E]LR0)@!@9.75&*H8P$-(I\C:H
M]W_'U^Q3<IK'.4:5;L<9 K;@S6P4:]UZ7J=MAEB#Y2->G6K&302/RZD'0MC,
MW28E6:.%T3$4-TX $1Y ',1\  /,1]FNRBZL=Y/IQ^7_ #RLG]V>\K<AO@RF
MYS!N8R9+9%MH-UXZ!:JI(Q-2H\ LX,Y"LT&HQX$AZI!$5,!UDF::LG+KD*^L
M4M-274]-YIA3"^0MP62J_B?%T(:>N-C;V*0;-A4%!FPA:A69>Y6NP2[SH4+'
MP=<K$#*S$J_4(8B#=J"92G<+MTE/V8+V_P":]S.1HG$N <87++61)E=NDWK-
M+AW$HX8H.%R(>ZMB?%*2)J5>;&."DA9;0_B(*/;D57=R"9$S:V ?#GX+M6X:
MNS[<3E#*CF!ON[W).WO*45;K/%%,^JV+:FK1YY\;&>-G;UHV>.DW;I%F[O5R
M4;,G%NDV$>S9,V-=A8]%V0 N/W/[^*US"*I'""#A/GW;A!%PGU!TF[M=(BR?
M47QZ3=!R]1?B'F'Q:[EC[\8&/_G H7ZXP>NBQO\ %D7_ )+C?]!;Z[UC[\8&
M/_G H7ZXP>BBMT@7R'\X_P"F;4)G:*O@>]W'\UA;[_\ %^ILR^0_G'_3-J$S
MM%7P/>[C^:PM]_\ B_17N]#]#]EJ]3>8_*/VZEPX#OPNFR'YP[M]R>4M1'F\
MQ^4?MU+AP'?A=-D/SAW;[D\I:*EOJ/J/NMJ8G_!I_F%_1#7WKX3_ (-/\POZ
M(:^]%>M<?VJ#%\A2^);"7U8$CQ>9-M^-II@LDW*D/I]"G+A19MLX6+XNW2"+
M:!7,LI^$3:OF;<>::*6JU^MG%QZ^%O-\1K;3!3>'VL:?<QM]?SEJQ@Q>>A,2
MY&KDVP10NF)%YUTJU1B'-@-'0\_5)&17-%-[97V$?("PCIR1E66M)OE#N^+;
MI/8XR74+-CW(-6>J1UDHUVA)"L6Z"?)<NMO*5^60;2+81 0.DMW)VCI$Q'#-
MPY;*)+'*EXX/U4AG#CXLNZGAD3=M/@Q:EVN@9">QLG>\3Y+BI"2J<U,1#-6-
M86.)DH22B+%4[*A&*C'K244]68RC-!@A.0TJ$9&'9V].$QVB6?W_ .ZF"VLY
M=P!2L0S%RI5XG*5;JAD:?LC2<M=/1:S_ +T5H"Q5F,49&>TY&QRJ,@G./%5G
M=?.W(P(F[ 4->H)3%\RB'R@(?;KU;!.:+UMSS/BS/6,7Q(_(&(+U7<@51=8?
M\$7E*\^(Z-%R1/)6(GV(O:_-(& 2+Q$J^1, @?1 XCCS\N5>*[5YLVGLE8#P
MUO(I4,K)NMN<M.4C*_H:)E7+3$^3740I%VISTAU>Y=0R#%QC.0.43 R8W9U)
MK DR8O%TZ#P@("(" @(#R$!\! 0\P$/B$-;@G;SG#!'$1VCU/*=::1-VPYN!
MQR]C;/3IM--^DW2F6#JNY!QE<&!DT@+)U^1-,U.Q,5$T^I9J== QF[AJX/KY
M.+QP,\W</N[67)6'*Y<,O;,WZJ\O!WV-8KV*RX99*J*'/3LR-XQ%1\WCH0O2
MC#94%BG69N+%J6RNH.RD<H2!9>/^X>A]?Z<*"FNV*?J%@@[75)R7K%IK$Q&V
M&M62OR+J'GJ]/PSM*0B)R$EF*B+R,EHM\@@\CW[55-=JY2353, AR&XWL6[5
MY*U2LP5!W\8@L%[?1*#:/_=XP>C!DL$TU;MBI%D+WBN<DH.,<3RRQ15DIBC3
M\>Q?F.95"FQZO656F8'(2E. @8AR@8ARB!B'*/B!R'#F4Y1#D(&*(E$! 0$0
MTT402/0_E\%LT*;VEOA)6DAS2N<;Y03E*J8$;M@;+S4QA3% "E(M7:O9FACJ
M]\?NB X Q@;.#F A 2,M^6_=IBX2]-:F7@\QY%R>X*AWQ8['V"LH*.53]*Y@
M; [N<%2XA!<3(ID$7,BBBF+IN=14J(K*(ZSGF(>0\M.8CYCST4N\_(?U_P J
MY9O [6E;;!$R-6V/[?34-TZ$Z267-P;F(L4RR;&#EWT#B:GR3J 2D2& #H/;
M1>9ADB B"]:=CRY5-L\[@\U[H,FSV9-P.2[3E;)=DZ"25IM;TCAPDQ1,)FD)
M"QS1%G"UFMQW,0C:U6XV)@F',RC>/(NJNLKXT<Q$R=XJ<B28"!>\5.5-/J,/
M(I>LXE+U&$0 I>?,1$  !$=3Q\,W@%;M=^,M WK(L+/[:-LJBS*0>Y+O===Q
M]WOT.<Z2RC3#M"F46C^3&0:B*:%\M#>-I4>54'T<6XKMSPRI8Y<[^?\ +^__
M "H98/$.2K'C+(&9H:G3#O%F+IBE5V]7H42H5Z#LF1)!2.IM;]-<'2+(6";4
M0<.TX>,!X^91#=29DDF<89!ROYQK9V[]^%ABZ/X..<=DFS_%C*$4J54890QM
M76!5Y2S7;*>-IZ#OCF5FY=8%)6V9'R*UK3VON)N154=R#V38QZ16\8W91[?6
M*&*)3& Q%$Q QRBFLF=%9,Q#F(=)9%0"J(KHJ%.DN@J4JJ"Q%$52$53.4"P6
MEJG5[.+G>&P?Q4L0,;'))Q4+G2FY"P&+M=<Z+;WR6]I%6:C-%>2J::BDO;J3
M&5YB18JH&D9MFFB4%U2#K85[\=HM+WU;3LR[8[LHC'MLDU95"MV11J1TO2K[
M#KI3=!NK5,Q>]%6L6IC&2+E!!1!5_&$D(HRI47RH#J$X&>G*K.PEHK$Q(5ZR
MUJ8B[#7+!$KF:RL#/P;]O*PDW&.2"!D)")E&C209*@/J.6R1A 2@(#M4.$%Q
M*:AQ*=JL!D!1S&QF=<?(Q=+W#T9J=)(T'?$V7-&U13(.A4M*R,U;JV6JN>[%
M%LH>7K*JRDE7'X:*;"/,?/S^O\EJ[LXX3R;MQR[D+!F9*PZI^3<865]5;? .
M0$2(/V@E5;2$8X 12D:_/QRS.>K,PW.HUEX"2CI%!02N!*7RKR\M;/\ XOG!
M4Q%Q,ZNA>:W(QN(]UM-A3QE+RM[FF<05PB&W>KLJ!EV/8)^Z,S5TG*JQH&PQ
MXGLU&<NW#B+)+0SB3K$IKP-XNPS=9L+NPTK<]B6;H(.W3AO6;P@8L[BV\I('
M$ =4O(D>G[@RIE$^A885\>(MC))0GNM6XXXBF!1<TCZ?/_*S=X<_'.WF\.V+
MBL<5]_#9MV\QSE51OA'*#J0*C6$'2H+/4<77V/*YL- 154ZUDX%5I9J2@Y6<
M+M:HR<.7#D]H["?:P=B-TCFB>;,5Y_P58E5DTWA6E<B,OT]L0X#UN$+!3))E
M9%6Z0@ &*YHK1UZW,K<Y2&,&O5$!#S 0Y@ AS 0\!\A\?B'XAUQH@<1\?R*V
M?['M&?!_>,F[M7=6XCU%TN],PD,(Y\0?MAYF#N7*">-%R)K>J ])5E"\C%'K
M\1 /'+CVH/A5UEDJY@[?G#(CHC919.,J.![C'N5UB*@D1F#R^GID4W75*(KE
M5<ODV94"CUN"K"1$^MDYC[1^O7&BSWG^7[_-6^]YG:PLLWR$EZ;LEPD3"B<@
M@9JGF+,+Z#NN0&":AN9W58QQ"D?4*&DBD]1K(V:P75!N816/7E%"DZ:DEMME
MHOMIL=WN]BF[?<KA-R5EM=KLDDZF+#9+#,.3O)6;FY5ZHJ[D))^Y4,JX<KJ&
M,/JI)@F@DDDGU\ $1Y  B(^0!XB/T:],Q%A?+F?[W'8QP?C.\9;R'*\S,J;C
MZN2-FG10*/X1\];,$CI0\4@',SF:FUXV&:$ 3NGZ)0$=%$DGU\UYD8Q2%,<Y
MBD(0ICG.8>12$* B8QA^("@ B/\ 4 CX:V0G9O>&[-[-MK$MGC+U</ Y[W4D
M@+(XA9%)1*;H6&8INJ[QM3Y9JLB12+L$VK*2E\M$:)O26"TW"04F1*0KRZ".
M'?!O[.'^XI9*?NFW^,H&?R=7W+2Q8SVXLW#*QU3'DZU51=1-LRG--CN(6YWB
M'<)@ZA:E#'?TFKOR(RCZ4M<R@P]P[@     !Y!\HC^41$?$1$?$1$1$1\1$1
MT4VMX\S^0_?V7.FFFBL33331$TTTT1=9N-*I^0JU,TR^5:NW6H6-DI&V&JVR
M%C;%6YV/5$HJ,9B#F&SR,DVAQ*43-WC59,1*4P% Q2B%?3=!V8GAQYV>REBQ
M;'Y!VJVI^"RQ28<G&C_'?IZPF.+A7&%Y96"%CVP*& PQU/D:BTZ0$B1$/5,6
MQCIHL$ ^HY5$+(W9"\[L'9?W(]YV)+4Q,<.HN2\4W6C/44Q#UA!>I62_M')R
MCX 0&C,I_P!]U$_>Z\[8]D;WHJ.T22>Z/:XS8F,8'+EC"Y?E':).@PE,@P7@
M(A)R85 (42'D6H%(8R@',) 34V .FBQV-^7]2J9F$^R&T)BO%2&XO>-<[2B5
M5)27JV%L;PE#;+)EY&5:(7"\2U\DP(<?4]+1K3)P4G,R9$CB EL-;/>$[L(V
M+N&T[M^V_5B(OZ+(&2V6+<O(Y"RJX()3$<&0N]P<RDC!%>%,(.VE5)7X]8O)
M,6?=%*0)&=-%D- ] N   #D <@_MX_E$?C'S'X]<Z::+*::::(N! !#D(<P\
MOH'S#Z?C]NL7LF[.-O\ E)9=_,4AO S;CJ%6?I:PU:25.83&.LZ28)^Y,@N8
MQA,9:1C':IA$1,<>8\\HM-?&S>NX'9:9H;!AL9FJ1/<*V3I5[L3'>G?&VQ')
MX4@'I)'VR-]6N!\U]O [+L.K76Y+6\WE<%?: />L3?LT)G-!Y\.1]:2,RQ$_
MBBD[XW#R<T@\*)RR<+."6%=2HY?G8_F8YF[6RUB,F2  B(D(J\BGT$J/2'(I
ME :B)O6-T (@ =!/PJ[6?F!LSUTQ1Y#Z]%DS>(>(#TC9A#F'Q&\1#XN6IH=-
M:BM>S5T7MRNF=IXA<[S+*N;V"O%SW=W+88LJV-GQ'#&M:!P W@+=5/VJ>N]*
M)L+-Y?,UH :^W@=9M3<  <.GGPSY9#Y<ETCWN)))<?-0U7?A,1V<*PE1]R%\
MH><*>Q0]%A8O)&'6EYE:Z@)# ):C=9VS(WVC=V;I[E.GVJ'1(7J$$RF$>K&^
MG=F"X7==O3>ZS]5RW>(Y,O6IC*<RQ96F,3.^^.J"X,(M5O>EFI2"F@$/(Y"D
M(DR:?X1LH*ARZL2Z:V=K&GX;4*@HX4Y=M1K R.OD=AS^9@@8""&5H,ODKT-1
MHXX#:L<( Y'H3SJ7;-SS>ZW3D,\S"/NO?XDMG&:QK>!GL2$<.DMSX+$XZ:Z]
MWF2ZY).>[SYY X\.P/MHV_;7Z@6A;><-XYPU41437<PF.ZG$UEO)NTB"F1_-
M+1[=-[.R()CT#(S3N0?&+X&<"'(->HVRL0]VJ]CIUA;J.H&UP,S6IILBY79J
MN(F>C743)().VITW+519B\73(X;J$70,8%4CE4(4P=@TURA<44!279GN$8BD
MB@G@O(()H(I()@.X?-PB":*94DP$PW(1,($(4!,(B(B',1$1U_1C.S9\)F(D
MXR78X/OR3Z(DXZ78J'W!9J5(F^BGS>19*'24N!DU2)NFJ)S)*%,FJ4HIJ%,0
MQBC/)IHL=K?D/T7 !R^L1^L1$?ZQUX%N@VS8BWA8/NNW?.T%(67%F0 @2V>%
MB[%.51\]"MV2(MD3W$]7'L?,L>XFX..<J>ANTO2$T3M5^MNLJF;W[3194!O]
M[1<(\?\ W&9 _P"T-FW_ %RU[5MTX$?#=VK9KQ_N"PQB2Y5_)^,91_,5"9DL
MTY6LK%@^DX"8K+M1Q!3]G?0\B12(G9% J3YHLFFHJ1P0I5T4CEF(TT6.T>O
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M6AO;+LXRUU2PAQ%^KDJ,/3_ UXK52U!<B>V+)Y[MYGK.=$YYC,;SVD M>UP
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%TT1?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
